DownloadHi-Res Photo

Maryam Lustberg, MD, MPH

Associate Professor of Internal Medicine (Medical Oncology); Director, Center for Breast Cancer; Chief, Breast Medical Oncology

Research & Publications
Biography
News

Research Summary

Improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment.

Extensive Research Description

Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship. Her research is focused on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment and also investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is a NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups.

Coauthors

Research Interests

Breast Neoplasms; Cancer Survivors; Chemotherapy-Related Cognitive Impairment

Selected Publications

Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathyLi Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A, Jin Y, Yang W, Huang K, Uddin M, Chen M, DiGiacomo D, Chen X, Razzaq S, Tonniges J, McTigue D, Mims A, Lustberg M, Wang Y, Hummon A, Evans W, Baker S, Cavaletti G, Sparreboom A, Hu S. Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy. JCI Insight 2023, 8: e164646. PMID: 37347545, PMCID: PMC10443802, DOI: 10.1172/jci.insight.164646.
Female reproductive health in pediatric, adolescent, and young adult cancer survivorsHoefgen H, Benoit J, Chan S, Jayasinghe Y, Lustberg M, Pohl V, Saraf A, Schmidt D, Appiah L. Female reproductive health in pediatric, adolescent, and young adult cancer survivors. Pediatric Blood & Cancer 2023, 70: e29170. PMID: 37381166, DOI: 10.1002/pbc.29170.
Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover TrialRenna M, Madison A, Peng J, Shrout M, Lustberg M, Ramaswamy B, Wesolowski R, VanDeusen J, Williams N, Sardesai S, Noonan A, Reinbolt R, Stover D, Cherian M, Malarkey W, Andridge R, Kiecolt-Glaser J. Worry and Mindfulness Differentially Impact Symptom Burden Following Treatment Among Breast Cancer Survivors: Findings From a Randomized Crossover Trial. Annals Of Behavioral Medicine 2023, 57: 888-898. PMID: 37335884, PMCID: PMC10498820, DOI: 10.1093/abm/kaad032.
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab.Noonan A, Farid S, Schnell P, Trunzo D, Malalur P, Jin N, Manne A, Abushahin L, Rahman S, Hays J, Elkhatib R, Mittra A, Roychowdhury S, Lustberg M, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab. Journal Of Clinical Oncology 2023, 41: e15613-e15613. DOI: 10.1200/jco.2023.41.16_suppl.e15613.
Trends in breast cancer death by stage at diagnoses in 2000-2018.Kahn A, Marczyk M, Silber A, Rozenblit M, Sanft T, DiGiovanna M, Schellhorn S, Krop I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. DOI: 10.1200/jco.2023.41.16_suppl.e18855.
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorshipLustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.
Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesityHaynam M, Chaplow Z, DeScenza V, Bowman J, Dispennette K, Zhang X, Kilar M, Hohn S, Fairman C, Lustberg M, Focht B. Design and methods of a translational, community-based, lifestyle weight management pilot intervention trial in breast cancer survivors with overweight or obesity. Contemporary Clinical Trials Communications 2023, 33: 101154. PMID: 37250507, PMCID: PMC10220259, DOI: 10.1016/j.conctc.2023.101154.
A review of the impact of energy balance on triple-negative breast cancerAkingbesote N, Owusu D, Liu R, Cartmel B, Ferrucci L, Zupa M, Lustberg M, Sanft T, Blenman K, Irwin M, Perry R. A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023, 2023: 104-124. PMID: 37139977, DOI: 10.1093/jncimonographs/lgad011.
Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.
A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorshipMadison A, Filatov M, Andridge R, Haas G, Povoski S, Agnese D, Lustberg M, Reinbolt R, Wesolowski R, Williams N, Malarkey W, Kiecolt-Glaser J. A troubled heart: Mood disorder history longitudinally predicts faster cardiopulmonary aging in breast cancer survivorship. PLOS ONE 2023, 18: e0283849. PMID: 37000800, PMCID: PMC10065250, DOI: 10.1371/journal.pone.0283849.
Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increasesMadison A, Renna M, Andridge R, Peng J, Shrout M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams N, Noonan A, Reinbolt R, Stover D, Cherian M, Malarkey W, Kiecolt-Glaser J. Conflicts hurt: social stress predicts elevated pain and sadness after mild inflammatory increases. Pain 2023, 164: 1985-1994. PMID: 36943254, PMCID: PMC10440304, DOI: 10.1097/j.pain.0000000000002894.
Online description of services provided in adult survivorship programs across U.S. accredited cancer centersAnampa-Guzmán A, Contreras-Chavez P, Lustberg M, Nekhlyudov L. Online description of services provided in adult survivorship programs across U.S. accredited cancer centers. Journal Of Cancer Survivorship 2023, 1-5. PMID: 36933086, DOI: 10.1007/s11764-023-01361-w.
Abstract P1-02-03: Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast CancerSukumar J, Sardesai S, Ni A, Williams N, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti-Mays M, Pariser A, Sudheendra P, George M, lustberg M. Abstract P1-02-03: Real World Treatment Patterns of Adjuvant Endocrine Therapy and Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer. Cancer Research 2023, 83: p1-02-03-p1-02-03. DOI: 10.1158/1538-7445.sabcs22-p1-02-03.
Abstract P1-10-10: Radiation Treatment Patterns for Elderly Women with Breast Cancer Brain MetastasesUpadhyay R, Perlow H, Williams N, Klamer B, White J, Bazan J, Jhawar S, Blakaj D, Grecula J, Arnett A, Thomas E, Chakravarti A, Raval R, Lustberg M, Palmer J, Beyer S. Abstract P1-10-10: Radiation Treatment Patterns for Elderly Women with Breast Cancer Brain Metastases. Cancer Research 2023, 83: p1-10-10-p1-10-10. DOI: 10.1158/1538-7445.sabcs22-p1-10-10.
Abstract P2-02-05: Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United StatesOdzer N, Chehayeb R, Lustberg M, Gross C, Foldi J. Abstract P2-02-05: Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States. Cancer Research 2023, 83: p2-02-05-p2-02-05. DOI: 10.1158/1538-7445.sabcs22-p2-02-05.
Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Cancer (MBC)Fanucci K, lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Abstract P2-23-09: Ultra-high Tumor Mutation Burden in Metastatic/Clinically Advanced Breast Cancer (MBC). Cancer Research 2023, 83: p2-23-09-p2-23-09. DOI: 10.1158/1538-7445.sabcs22-p2-23-09.
Abstract P6-09-05: Using Mixed Methods to Examine Clinician and Patient Use of Terminology to Describe Trastuzumab BiosimilarsPapautsky E, Salunke D, Montague H, Carlson M, Johnson S, Attai D, Lustberg M. Abstract P6-09-05: Using Mixed Methods to Examine Clinician and Patient Use of Terminology to Describe Trastuzumab Biosimilars. Cancer Research 2023, 83: p6-09-05-p6-09-05. DOI: 10.1158/1538-7445.sabcs22-p6-09-05.
Abstract PD12-01: PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019Puklin L, Li F, Cartmel B, Sanft T, Lisevick A, Winer E, Lustberg M, Sharifi M, Irwin M, Ferrucci L. Abstract PD12-01: PD12-01 Impact of obesity and post-diagnosis weight change on survival in women with breast cancer diagnosed at Smilow Cancer Hospital from 2013-2019. Cancer Research 2023, 83: pd12-01-pd12-01. DOI: 10.1158/1538-7445.sabcs22-pd12-01.
Biomechanical Effect of Music and Dance on Postural Control Among Breast Cancer Survivors With NeuropathyWorthen-Chaudhari L, Bland C, WIlder J, Wali R, Bibi A, Taha S, Costa-GIomi E, Crasta J, Schnell P, Hackney M, Lustberg M. Biomechanical Effect of Music and Dance on Postural Control Among Breast Cancer Survivors With Neuropathy. Archives Of Physical Medicine And Rehabilitation 2023, 104: e14-e15. DOI: 10.1016/j.apmr.2022.12.039.
Case Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait StabilityGlover N, WIlder J, Patrick S, Hackney M, Lustberg M, Worthen-Chaudhari L. Case Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait Stability. Archives Of Physical Medicine And Rehabilitation 2023, 104: e16. DOI: 10.1016/j.apmr.2022.12.044.
Effect of Partnered Dance Intervention on Upper Extremity Outcomes for Breast Cancer Survivors With CIPNBland C, Worthen-Chaudhari L, Hackney M, Lustberg M, Crasta J. Effect of Partnered Dance Intervention on Upper Extremity Outcomes for Breast Cancer Survivors With CIPN. Archives Of Physical Medicine And Rehabilitation 2023, 104: e24. DOI: 10.1016/j.apmr.2022.12.067.
Sensorimotor Cortical Thickness Changes Following Taxane-Based Chemotherapy: Support for a CNS Role in CIPN?Worthen-Chaudhari L, Monfort S, Chaudhari A, Lustberg M. Sensorimotor Cortical Thickness Changes Following Taxane-Based Chemotherapy: Support for a CNS Role in CIPN? Archives Of Physical Medicine And Rehabilitation 2023, 104: e51. DOI: 10.1016/j.apmr.2022.12.148.
Goal Attainment Scaling with a Dance-Based Intervention for Breast Cancer Survivors With CIPN: Pilot StudyBland C, Worthen-Chaudhari L, Hackney M, Crasta J, Lustberg M. Goal Attainment Scaling with a Dance-Based Intervention for Breast Cancer Survivors With CIPN: Pilot Study. Archives Of Physical Medicine And Rehabilitation 2023, 104: e31-e32. DOI: 10.1016/j.apmr.2022.12.089.
Hair loss during and after breast cancer therapyRose L, Lustberg M, Ruddy K, Cathcart-Rake E, Loprinzi C, Dulmage B. Hair loss during and after breast cancer therapy. Supportive Care In Cancer 2023, 31: 186. PMID: 36826602, DOI: 10.1007/s00520-023-07634-5.
Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancerLustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Leveraging GWAS data derived from a large cooperative group trial to assess the risk of taxane-induced peripheral neuropathy (TIPN) in patients being treated for breast cancer: Part 2—functional implications of a SNP cluster associated with TIPN risk in patients being treated for breast cancer. Supportive Care In Cancer 2023, 31: 178. PMID: 36809570, DOI: 10.1007/s00520-023-07617-6.
Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trialLustberg M, Wu X, Fernández-Martínez J, de Andrés-Galiana E, Philips S, Leibowitz J, Schneider B, Sonis S. Identification of a SNP cluster associated with taxane-induced peripheral neuropathy risk in patients being treated for breast cancer using GWAS data derived from a large cooperative group trial. Supportive Care In Cancer 2023, 31: 139. PMID: 36707490, DOI: 10.1007/s00520-023-07595-9.
The Rise of Supportive Oncology: A Revolution in Cancer CareBerman R, Laird B, Minton O, Monnery D, Ahamed A, Boland E, Droney J, Vidrine J, Leach C, Scotté F, Lustberg M, Lacey J, Chan R, Duffy T, Noble S. The Rise of Supportive Oncology: A Revolution in Cancer Care. Clinical Oncology 2023, 35: 213-215. PMID: 36737312, DOI: 10.1016/j.clon.2023.01.015.
Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701)Ruddy K, Zahrieh D, He J, Waechter B, Holleran J, Lewis L, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo H, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars In Oncology 2023, 50: 7-10. PMID: 36693773, PMCID: PMC10247389, DOI: 10.1053/j.seminoncol.2023.01.001.
Retrospective cohort study of scalp cooling in breast cancer patientsRose L, Schnell P, Radcliff L, Lustberg M, Dulmage B. Retrospective cohort study of scalp cooling in breast cancer patients. Supportive Care In Cancer 2023, 31: 118. PMID: 36645520, DOI: 10.1007/s00520-022-07562-w.
Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?Williams N, Grimm M, Gast K, Lustberg M. Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today? Current Breast Cancer Reports 2022, 14: 142-152. DOI: 10.1007/s12609-022-00463-1.
Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse ModelYoung N, Hampton J, Sharma J, Jablonski K, DeVries C, Bratasz A, Wu L, Lustberg M, Reinbolt R, Jarjour W. Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model. Pharmaceuticals 2022, 15: 1578. PMID: 36559029, PMCID: PMC9785754, DOI: 10.3390/ph15121578.
Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) StudyYang Y, McLaughlin E, Naughton M, Lustberg M, Nolan T, Kroenke C, Weitlauf J, Saquib N, Shadyab A, Follis S, Pan K, Paskett E. Social Support, social ties, and cognitive function of women with breast cancer: findings from the Women’s Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study. Supportive Care In Cancer 2022, 31: 48. PMID: 36525119, PMCID: PMC9758078, DOI: 10.1007/s00520-022-07505-5.
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction ChemotherapyLockwood B, El-Jawahri A, Walker A, Ehrman S, Russell D, Kale S, Gustin J, Bose-Brill S, LeBlanc T, Luger S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Journal Of Adolescent And Young Adult Oncology 2022, 12: 592-598. PMID: 36367711, DOI: 10.1089/jayao.2022.0082.
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral NeurotoxicityNepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. PMID: 36506732, PMCID: PMC9730833, DOI: 10.1158/2767-9764.crc-22-0172.
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral NeurotoxicityNepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y, DiGiacomo D, Gibson A, Lustberg M, Hu S, Sparreboom A. Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity. Cancer Research Communications 2022, 2: 1334-1343. DOI: 10.1158/2767-9764.crc-22-0172.
The Association of Serum Inflammatory Markers and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing ChemotherapyZhang Z, Schnell P, Ormiston K, Weinhold K, Kopec R, Lustberg M, Orchard T. The Association of Serum Inflammatory Markers and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy. Current Developments In Nutrition 2022, 6: 6009258. PMCID: PMC9193788, DOI: 10.1093/cdn/nzac052.025.
The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer PatientsBennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Omega-9, Omega-3 Fatty Acids and Plasmalogen in Breast Cancer Patients. Current Developments In Nutrition 2022, 6: 6009237. PMCID: PMC9193887, DOI: 10.1093/cdn/nzac052.004.
The mutational profile of ER-, PR+, HER2- metastatic breast cancer.Fischbach N, Huang R, Lustberg M, Pelletier M, Pusztai L, Sivakumar S, Sokol E, Ross J, Levy M. The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Journal Of Clinical Oncology 2022, 40: 1025-1025. DOI: 10.1200/jco.2022.40.16_suppl.1025.
Treatment patterns and medical costs of metastatic breast cancer care in the United States.Jaber Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.
Levering internet-based discussion data from gynecological cancer survivors to inform survivorship care: A mixed methods thematic analysis approach.Adams E, Tallman D, Haynam M, Nekhlyudov L, Lustberg M. Levering internet-based discussion data from gynecological cancer survivors to inform survivorship care: A mixed methods thematic analysis approach. Journal Of Clinical Oncology 2022, 40: e24143-e24143. DOI: 10.1200/jco.2022.40.16_suppl.e24143.
Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.Sukumar J, Vaughn J, Stein J, Schnell P, Sudheendra P, Pariser A, Gatti-Mays M, Williams N, Cherian M, Stover D, Wesolowski R, Ramaswamy B, Lustberg M, Sardesai S. Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors. Journal Of Clinical Oncology 2022, 40: tps12139-tps12139. DOI: 10.1200/jco.2022.40.16_suppl.tps12139.
A Global Survey on the Utilization of Cryotherapy and Compression Therapy for the Prevention of Chemotherapy-Induced Peripheral NeuropathyChan A, Elsayed A, Ng D, Ruddy K, Loprinzi C, Lustberg M. A Global Survey on the Utilization of Cryotherapy and Compression Therapy for the Prevention of Chemotherapy-Induced Peripheral Neuropathy. 2022 DOI: 10.21203/rs.3.rs-1757410/v1.
Targetable genomic mutations in young women with advanced breast cancer.Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Targetable genomic mutations in young women with advanced breast cancer. Journal Of Clinical Oncology 2022, 40: 1027-1027. DOI: 10.1200/jco.2022.40.16_suppl.1027.
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast CancerQuiroga D, Pinette A, Benner B, Schwarz E, Wesolowski R, Stiff A, Zelinskas S, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer. Journal Of The National Comprehensive Cancer Network 2022, 20: clo22-079. DOI: 10.6004/jnccn.2021.7196.
Abstract P2-13-13: The patient-centered paradox: A US-based survey of physician- and patient-reported experiences with biosimilar trastuzumabPapautsky E, Carlson M, Lustberg M. Abstract P2-13-13: The patient-centered paradox: A US-based survey of physician- and patient-reported experiences with biosimilar trastuzumab. Cancer Research 2022, 82: p2-13-13-p2-13-13. DOI: 10.1158/1538-7445.sabcs21-p2-13-13.
Abstract P4-09-08: Examining neurocognitive function in breast-cancer patients after chemotherapySharpe J, Palettas M, Grimm M, Kassem M, Ramaswamy B, Wesolowski R, Williams N, Sardesai S, Stover D, VanDeusen J, Cherian M, Pariser A, Gatti-Mays M, Lustberg M, Boxley L. Abstract P4-09-08: Examining neurocognitive function in breast-cancer patients after chemotherapy. Cancer Research 2022, 82: p4-09-08-p4-09-08. DOI: 10.1158/1538-7445.sabcs21-p4-09-08.
Abstract P4-10-09: Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)Loeser A, Bardia A, Burkard M, Kalinsky K, Peppercorn J, Rugo H, Carlson M, Cowden J, Maues J, McGlown S, Lustberg M. Abstract P4-10-09: Patient-centered dosing: Oncologists’ perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC). Cancer Research 2022, 82: p4-10-09-p4-10-09. DOI: 10.1158/1538-7445.sabcs21-p4-10-09.
Abstract P4-10-11: Eyebrow/eyelash loss among survivorsCathcart-Rake E, Loprinzi C, Couch F, Olson J, Dulmage B, Lustberg M, Larson N, Ruddy K. Abstract P4-10-11: Eyebrow/eyelash loss among survivors. Cancer Research 2022, 82: p4-10-11-p4-10-11. DOI: 10.1158/1538-7445.sabcs21-p4-10-11.
Abstract P4-10-17: Alopecia among breast cancer survivorsCathcart-Rake E, Loprinzi C, Olson J, Couch F, Dulmage B, Lustberg M, Larson N, Ruddy K. Abstract P4-10-17: Alopecia among breast cancer survivors. Cancer Research 2022, 82: p4-10-17-p4-10-17. DOI: 10.1158/1538-7445.sabcs21-p4-10-17.
Abstract P3-09-09: Serial circulating tumor DNA from patients with metastatic breast cancer with and without BRCA1/2 mutationsCollier K, Tallman D, Weber Z, Haynam M, Adams E, Jenison J, Asad S, Lustberg M, Cherian M, Ramaswamy B, Sardesai S, Williams N, Wesolowski R, Vandeusen J, Gatti-Mays M, Pariser A, Mortazavi A, Stover D. Abstract P3-09-09: Serial circulating tumor DNA from patients with metastatic breast cancer with and without BRCA1/2 mutations. Cancer Research 2022, 82: p3-09-09-p3-09-09. DOI: 10.1158/1538-7445.sabcs21-p3-09-09.
Abstract 6937: Atrial Fibrillation in Breast Cancer Patients: Incidence, Prevalence, Risk Factors, and Mortality: Longitudinal Seer-Medicare AnalysisGuha A, Fradley M, Dent S, Weintraub N, Lustberg M, Alonso A, Addison D. Abstract 6937: Atrial Fibrillation in Breast Cancer Patients: Incidence, Prevalence, Risk Factors, and Mortality: Longitudinal Seer-Medicare Analysis. Circulation 2021, 144: a6937-a6937. DOI: 10.1161/circ.144.suppl_1.6937.
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysisGuha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. European Heart Journal 2021, 43: ehab745. PMID: 34791123, PMCID: PMC8914878, DOI: 10.1093/eurheartj/ehab745.
Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapyOrmiston K, Gaudier-Diaz MM, TinKai T, Fitzgerald J, Cole RM, Andridge R, Lustberg M, DeVries AC, Orchard T. Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapy. Nutritional Neuroscience 2021, 25: 2650-2658. PMID: 34772330, PMCID: PMC9095756, DOI: 10.1080/1028415x.2021.1998296.
Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS).Gupta A, Nshuti L, Grewal U, Sedhom R, Parsons H, Blaes A, Virnig B, Lustberg M, Subbiah I, Nipp R, Dy S, Dusetzina S. Limited benefit and high financial burden of drugs used to manage cancer-associated anorexia/cachexia syndrome (CACS). Journal Of Clinical Oncology 2021, 39: 55-55. DOI: 10.1200/jco.2020.39.28_suppl.55.
Financial Burden of Drugs Prescribed for Cancer-Associated SymptomsGupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, Blaes AH, Virnig BA, Lustberg MB, Subbiah IM, Nipp RD, Dy SM, Dusetzina SB. Financial Burden of Drugs Prescribed for Cancer-Associated Symptoms. JCO Oncology Practice 2021, 18: 140-147. PMID: 34558297, PMCID: PMC9213200, DOI: 10.1200/op.21.00466.
Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancerSukumar JS, Quiroga D, Kassem M, Grimm M, Shinde NV, Appiah L, Palettas M, Stephens J, Gatti-Mays ME, Pariser A, Cherian M, Stover DG, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. Breast Cancer Research And Treatment 2021, 190: 183-188. PMID: 34498153, PMCID: PMC8560558, DOI: 10.1007/s10549-021-06368-4.
Perspectives of adolescent and young adult cancer survivors: review of community-based discussion boardsSmith A, Fogarasi M, Lustberg MB, Nekhlyudov L. Perspectives of adolescent and young adult cancer survivors: review of community-based discussion boards. Journal Of Cancer Survivorship 2021, 16: 1079-1089. PMID: 34471949, DOI: 10.1007/s11764-021-01098-4.
Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing ChemotherapyZhang Z, Ormiston K, Weinhold K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Inflammatory Markers and Correlations with Serum Polyunsaturated Fatty Acids In Postmenopausal Women With Breast Cancer Undergoing Chemotherapy. Journal Of The Academy Of Nutrition And Dietetics 2021, 121: a18. DOI: 10.1016/j.jand.2021.06.034.
316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert surveyVukovic P, Meattini I, Lambertini M, de Azambuja E, Prat A, Aftimos P, Lustberg M, Kruljac I, Morgan G. 316P Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey. Annals Of Oncology 2021, 32: s502-s503. DOI: 10.1016/j.annonc.2021.08.599.
Future research in cancer survivorshipChan RJ, Nekhlyudov L, Duijts SFA, Hudson SV, Jones JM, Keogh J, Love B, Lustberg MB, Mehnert-Theuerkauf A, Nathan P, Ness KK, Sheppard VB, Smith K, Tevaarwerk A, Yu X, Feuerstein M. Future research in cancer survivorship. Journal Of Cancer Survivorship 2021, 15: 659-667. PMID: 34460055, DOI: 10.1007/s11764-021-01102-x.
Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in HospicePrater LC, O’Rourke B, Schnell P, Xu W, Li Y, Gustin J, Lockwood B, Lustberg M, White S, Happ MB, Retchin SM, Wickizer TM, Bose-Brill S. Examining the Association of Billed Advance Care Planning With End-of-Life Hospital Admissions Among Advanced Cancer Patients in Hospice. American Journal Of Hospice And Palliative Medicine® 2021, 39: 504-510. PMID: 34427154, DOI: 10.1177/10499091211039449.
Effects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic reviewAddison S, Shirima D, Aboagye-Mensah EB, Dunovan SG, Pascal EY, Lustberg MB, Arthur EK, Nolan TS. Effects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic review. Journal Of Cancer Survivorship 2021, 16: 1023-1046. PMID: 34357555, PMCID: PMC8342979, DOI: 10.1007/s11764-021-01094-8.
Erythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast CancerBelury MA, Cole RM, Andridge R, Keiter A, Raman SV, Lustberg MB, Kiecolt-Glaser JK. Erythrocyte Long-Chain ω-3 Fatty Acids Are Positively Associated with Lean Mass and Grip Strength in Women with Recent Diagnoses of Breast Cancer. Journal Of Nutrition 2021, 151: 2125-2133. PMID: 34036350, PMCID: PMC8349126, DOI: 10.1093/jn/nxab109.
Preliminary Efficacy Of A Community-based, Group-mediated Cognitive Behavioral Lifestyle Intervention Among Breast Cancer SurvivorsHaynam M, Fairman C, Bowman J, DeScenza V, Chaplow Z, Kilar M, Dispennette K, Hohn S, Zhang X, Lustberg M, Focht B. Preliminary Efficacy Of A Community-based, Group-mediated Cognitive Behavioral Lifestyle Intervention Among Breast Cancer Survivors. Medicine & Science In Sports & Exercise 2021, 53: 480-480. DOI: 10.1249/01.mss.0000764868.45231.6d.
Initial Feasibility And Acceptability Of A Community-based Lifestyle Intervention Among Breast Cancer SurvivorsDeScenza V, Fairman C, Haynam M, Bowman J, Chaplow Z, Kilar M, Dispennette K, Zhang X, Hohn S, Lustberg M, Focht B. Initial Feasibility And Acceptability Of A Community-based Lifestyle Intervention Among Breast Cancer Survivors. Medicine & Science In Sports & Exercise 2021, 53: 480-480. DOI: 10.1249/01.mss.0000764876.19641.83.
Effects Of A Community-Based Lifestyle Intervention On Resistance Training And Balance Outcomes Among Breast Cancer SurvivorsChaplow Z, Haynam M, DeScenza V, Bowman J, Dispennette K, Zhang X, Kilar M, Hohn S, Fairman C, Lustberg M, Focht B. Effects Of A Community-Based Lifestyle Intervention On Resistance Training And Balance Outcomes Among Breast Cancer Survivors. Medicine & Science In Sports & Exercise 2021, 53: 481-481. DOI: 10.1249/01.mss.0000764884.17577.ae.
SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathyQvortrup C, Muro K, Lustberg M, Persson A, Näsström J, Carlsson S, Nagahama F, Pfeiffer P. SO-17 The global POLAR program: Top-line results of placebo-controlled studies of calmangafodipir on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy. Annals Of Oncology 2021, 32: s209-s210. DOI: 10.1016/j.annonc.2021.05.041.
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)Hertz DL, Childs DS, Park SB, Faithfull S, Ke Y, Ali NT, McGlown SM, Chan A, Grech LB, Loprinzi CL, Ruddy KJ, Lustberg M. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews 2021, 99: 102241. PMID: 34174668, DOI: 10.1016/j.ctrv.2021.102241.
Supportive Care: Low Cost, High Value.Popescu RA, Roila F, Arends J, Metro G, Lustberg M. Supportive Care: Low Cost, High Value. American Society Of Clinical Oncology Educational Book 2021, 41: 1-11. PMID: 33830830, DOI: 10.1200/edbk_320041.
Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast CancerVaughn JE, Ammermann C, Lustberg MB, Bickel WK, Stein JS. Delay Discounting and Adjuvant Endocrine Therapy Adherence in Hormone Receptor-Positive Breast Cancer. Health Psychology 2021, 40: 398-407. PMID: 34323542, DOI: 10.1037/hea0001077.
The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer PatientsBennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients. Current Developments In Nutrition 2021, 5: 70. PMCID: PMC8180829, DOI: 10.1093/cdn/nzab034_004.
Changes in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy TreatmentZhang Z, Ormiston K, Schnell P, Kopec R, Lustberg M, Orchard T. Changes in Serum Fatty Acids and Inflammatory Markers in Postmenopausal Women With Breast Cancer Following Chemotherapy Treatment. Current Developments In Nutrition 2021, 5: 5140290. PMCID: PMC8182042, DOI: 10.1093/cdn/nzab036_032.
A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility StudyZvinovski F, Stephens JA, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Mehta L, Foraker R, Gulati M, Lustberg M, Quick AM. A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study. Journal Of Oncology 2021, 2021: 9965583. PMID: 34135964, PMCID: PMC8178006, DOI: 10.1155/2021/9965583.
Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations.Collier K, Tallman D, Weber Z, Haynam M, Adams E, Jenison J, Asad S, Lustberg M, Cherian M, Ramaswamy B, Sardesai S, Williams N, Wesolowski R, VanDeusen J, Gatti-Mays M, Pariser A, Mortazavi A, Stover D. Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations. Journal Of Clinical Oncology 2021, 39: 1025-1025. DOI: 10.1200/jco.2021.39.15_suppl.1025.
Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.
Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States.Williams N, Paxman R, Thornhill E, Kassem M, Grimm M, Dulmage B, Cathcart-Rake E, Ruddy K, Pariser A, Gatti-Mays M, Cherian M, VanDeusen J, Stover D, Sardesai S, Wesolowski R, Ramaswamy B, Loprinzi C, Lustberg M. Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. Journal Of Clinical Oncology 2021, 39: e18739-e18739. DOI: 10.1200/jco.2021.39.15_suppl.e18739.
Preliminary efficacy of a community-based, group-mediated cognitive behavioral lifestyle intervention among breast cancer survivors.Haynam M, Fairman C, Bowman J, DeScenza V, Chaplow Z, Kilar M, Dispennette K, Hohn S, Zhang X, Lustberg M, Focht B. Preliminary efficacy of a community-based, group-mediated cognitive behavioral lifestyle intervention among breast cancer survivors. Journal Of Clinical Oncology 2021, 39: e24035-e24035. DOI: 10.1200/jco.2021.39.15_suppl.e24035.
Genetic testing documentation in survivorship care plans in patients with breast cancer.Kaur K, Shinde N, Klemanski D, Xu M, Aeilts A, Lustberg M, Jeter J. Genetic testing documentation in survivorship care plans in patients with breast cancer. Journal Of Clinical Oncology 2021, 39: e24110-e24110. DOI: 10.1200/jco.2021.39.15_suppl.e24110.
Association of pathological complete response rates and TILs in triple-negative breast cancer patients.Kassem M, Goldstein D, Schnell P, Grimm M, Quiroga D, Miah A, Vargo C, Shinde N, Michael B, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai S, Wesolowski R, Lustberg M, Ramaswamy B, Tozbikian G, Cherian M. Association of pathological complete response rates and TILs in triple-negative breast cancer patients. Journal Of Clinical Oncology 2021, 39: e12596-e12596. DOI: 10.1200/jco.2021.39.15_suppl.e12596.
Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study.Grimm M, Ramaswamy B, Lustberg M, Wesolowski R, Sardesai S, VanDeusen J, Cherian M, Stover D, Gatti-Mays M, Pariser A, Kassem M, Stephens J, Palettas M, Williams N. Survival outcomes in patients with IDC and ILC breast cancer: A well matched single institution study. Journal Of Clinical Oncology 2021, 39: e13056-e13056. DOI: 10.1200/jco.2021.39.15_suppl.e13056.
Cardiotoxic safety communications after FDA approval of novel cancer therapies.Bonsu J, Kola-Kehinde O, Kim L, Ruz P, Lustberg M, Brammer J, Addison D. Cardiotoxic safety communications after FDA approval of novel cancer therapies. Journal Of Clinical Oncology 2021, 39: e18629-e18629. DOI: 10.1200/jco.2021.39.15_suppl.e18629.
Racial and ethnic disparities among patients with breast cancer and COVID-19.Nagaraj G, Accordino M, French B, Kuderer N, Lyman G, Stover D, Blinder V, Schmidt A, Shatsky R, Grover P, Puc M, Hwang C, Wulff-Burchfield E, Lewis M, Menendez A, Bilen M, Warner J, Lustberg M, Shah D. Racial and ethnic disparities among patients with breast cancer and COVID-19. Journal Of Clinical Oncology 2021, 39: 6500-6500. DOI: 10.1200/jco.2021.39.15_suppl.6500.
Genomic features of rapid versus late relapse in triple negative breast cancerZhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer 2021, 21: 568. PMID: 34006255, PMCID: PMC8130400, DOI: 10.1186/s12885-021-08320-7.
Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor useAmigo M, Hoffman K, Chung C, Lustberg M, Wesolowski R, VanDeusen J, Stover D, Suarez GT, Cherian M, Kaffenberger B, Dulmage B. Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use. Journal Of The American Academy Of Dermatology 2021, 86: 1346-1348. PMID: 33961922, DOI: 10.1016/j.jaad.2021.04.092.
Introduction to special section: Living with Incurable Cancer: Addressing Gaps in Cancer SurvivorshipLustberg MB, Carlson M, Nekhlyudov L. Introduction to special section: Living with Incurable Cancer: Addressing Gaps in Cancer Survivorship. Journal Of Cancer Survivorship 2021, 15: 367-369. PMID: 33945110, DOI: 10.1007/s11764-021-01047-1.
Developing a global cancer survivorship community: the Journal of Cancer Survivorship Social Media Site @jcansurvLustberg MB, Nekhlyudov L, Jones JM, Love B, Katz MS, Feuerstein M. Developing a global cancer survivorship community: the Journal of Cancer Survivorship Social Media Site @jcansurv. Journal Of Cancer Survivorship 2021, 15: 481-484. PMID: 33788171, PMCID: PMC8011364, DOI: 10.1007/s11764-021-01034-6.
BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast CancerSukumar J, Quiroga D, Kassem M, Grimm M, Shinde N, Appiah L, Palettas M, Stephens J, Cherian M, Stover D, Williams N, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B, Sardesai S. BPI21-008: Patient Preferences and Treatment Adherence to Adjuvant Ovarian Suppression Among Premenopausal Women With Hormone Receptor Positive Breast Cancer. Journal Of The National Comprehensive Cancer Network 2021, 19: bpi21-008. DOI: 10.6004/jnccn.2020.7759.
Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemicPark KU, Gregory M, Bazan J, Lustberg M, Rosenberg S, Blinder V, Sharma P, Pusztai L, Shen C, Partridge A, Thompson A. Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. Breast Cancer Research And Treatment 2021, 188: 249-258. PMID: 33651271, PMCID: PMC7921279, DOI: 10.1007/s10549-021-06153-3.
Abstract PS13-46: Immunomodulation with dexamethasone in neoadjuvant chemotherapy for triple negative breast cancerGoldstein D, Kassem M, Quiroga D, Miah A, Vargo C, Shinde N, Berger M, Williams N, Stover D, Sardesai S, Lustberg M, Ramaswamy B, Tozbikian G, Schnell P, Cherian M. Abstract PS13-46: Immunomodulation with dexamethasone in neoadjuvant chemotherapy for triple negative breast cancer. Cancer Research 2021, 81: ps13-46-ps13-46. DOI: 10.1158/1538-7445.sabcs20-ps13-46.
Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort studyKhaki A, Shah D, Lustberg M, Accordino M, Stover D, Nagaraj G, Rivera D, Perez E, Tolaney S, Peppercorn J, Grivas P, Warner J, Painter C, de Lima Lopes G, Peters S, Thompson M, Choueiri T, Rini B, Lyman G, Kuderer N, Vinayak S. Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study. Cancer Research 2021, 81: ps7-01-ps7-01. DOI: 10.1158/1538-7445.sabcs20-ps7-01.
Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancerPark K, Gregory M, Lustberg M, Bazan J, Shen C, Rosenberg S, Blinder V, Sharma P, Pusztai L, Partridge A, Thompson A. Abstract SS2-05: Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer. Cancer Research 2021, 81: ss2-05-ss2-05. DOI: 10.1158/1538-7445.sabcs20-ss2-05.
Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancerGeorge M, Williams N, Lustberg M, Omene C, Chan N, Ohri N, Kowzun M, Potdevin L, Eladoumikdachi F, Kumar S, Wesolowski R, Wilkinson G, Tang D, Kim S, Ganesan S, Haffty B, Toppmeyer D. Abstract OT-32-02: Irene study: Phase 2 study of incmga00012 (retifanlimab)and the oncolytic virus pelareorep in metastatic triple negative breast cancer. Cancer Research 2021, 81: ot-32-02-ot-32-02. DOI: 10.1158/1538-7445.sabcs20-ot-32-02.
Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral NeuropathyLi Y, Lustberg MB, Hu S. Emerging Pharmacological and Non-Pharmacological Therapeutics for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. Cancers 2021, 13: 766. PMID: 33673136, PMCID: PMC7918689, DOI: 10.3390/cancers13040766.
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated ArthralgiasSchnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.
Triple-negative breast cancer: promising prognostic biomarkers currently in developmentSukumar J, Gast K, Quiroga D, Lustberg M, Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Review Of Anticancer Therapy 2021, 21: 135-148. PMID: 33198517, PMCID: PMC8174647, DOI: 10.1080/14737140.2021.1840984.
Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapyQuick AM, Zvinovski F, Hudson C, Hundley A, Evans C, Stephens JA, Arthur E, Ramaswamy B, Reinbolt RE, Noonan AM, VanDeusen JB, Wesolowski R, Stover DG, Williams NO, Sardesai SD, Faubion SS, Loprinzi CL, Lustberg MB. Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy. Menopause The Journal Of The North American Menopause Society 2021, 28: 642-649. PMID: 33534429, DOI: 10.1097/gme.0000000000001738.
Targeting OCT3 attenuates doxorubicin-induced cardiac injuryHuang KM, Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020168118. PMID: 33495337, PMCID: PMC7865186, DOI: 10.1073/pnas.2020168118.
Dissemination of cancer survivorship care plans: who is being left out?Timsina LR, Zarzaur B, Haggstrom DA, Jenkins PC, Lustberg M, Obeng-Gyasi S. Dissemination of cancer survivorship care plans: who is being left out? Supportive Care In Cancer 2021, 29: 4295-4302. PMID: 33415363, DOI: 10.1007/s00520-020-05915-x.
Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case SeriesBlow T, Hyde PN, Falcone JN, Neinstein A, Vasan N, Chitkara R, Hurd MA, Sardesai S, Lustberg MB, Flory JH, Volek JS, Goncalves MD. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series. Integrative Cancer Therapies 2021, 20: 15347354211032283. PMID: 34259084, PMCID: PMC8283040, DOI: 10.1177/15347354211032283.
Readdressing the Needs of Cancer Survivors During COVID-19: A Path ForwardJones JM, Saeed H, Katz MS, Lustberg MB, Forster VJ, Nekhlyudov L. Readdressing the Needs of Cancer Survivors During COVID-19: A Path Forward. Journal Of The National Cancer Institute 2020, 113: djaa200. PMID: 33367655, PMCID: PMC7799033, DOI: 10.1093/jnci/djaa200.
The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation OncologyJhawar SR, Palmer JD, Wang SJ, Bitterman D, Klamer B, Huynh-Le M, Chung C, Ohri N, Stover DG, Lustberg MB, Mishra S, Warner J, Jabbour S, Goyal S, Group C. The COVID-19 & Cancer Consortium (CCC19) and Opportunities for Radiation Oncology. Advances In Radiation Oncology 2020, 6: 100614. PMID: 33521393, PMCID: PMC7834122, DOI: 10.1016/j.adro.2020.10.026.
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivorsQuick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, Coleman JS, Wang KC, Lustberg M. Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas 2020, 144: 37-44. PMID: 33358206, PMCID: PMC7773136, DOI: 10.1016/j.maturitas.2020.10.018.
Abstract PR06: Different places, same problems: Tales of Deep South and Midwestern young African American breast cancer survivorship careNolan T, Addison S, Andersen B, Lustberg M. Abstract PR06: Different places, same problems: Tales of Deep South and Midwestern young African American breast cancer survivorship care. Cancer Epidemiology Biomarkers & Prevention 2020, 29: pr06-pr06. DOI: 10.1158/1538-7755.disp20-pr06.
Abstract PO-063: A systematic review of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomesAddison S, Shirima D, Dunovan S, Lustberg M, Arthur E, Nolan T. Abstract PO-063: A systematic review of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes. Cancer Epidemiology Biomarkers & Prevention 2020, 29: po-063-po-063. DOI: 10.1158/1538-7755.disp20-po-063.
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study GroupMayo SJ, Lustberg M, M. Dhillon H, Nakamura ZM, Allen DH, Von Ah D, C. Janelsins M, Chan A, Olson K, Tan CJ, Toh YL, Oh J, Grech L, Cheung YT, Subbiah IM, Petranovic D, D’Olimpio J, Gobbo M, Koeppen S, Loprinzi CL, Pang L, Shinde S, Ntukidem O, Peters KB. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Supportive Care In Cancer 2020, 29: 2821-2840. PMID: 33231809, DOI: 10.1007/s00520-020-05860-9.
Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction ChemotherapyLockwood B, El-Jawahri A, Walker A, Russell D, Gustin J, Ehrman S, Bose-Brill S, Lustberg M, Bhatnagar B. Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy. Blood 2020, 136: 17-18. DOI: 10.1182/blood-2020-140589.
Worry and rumination in breast cancer patients: perseveration worsens self-rated healthRenna ME, Rosie Shrout M, Madison AA, Lustberg M, Povoski SP, Agnese DM, Reinbolt RE, Wesolowski R, Williams NO, Ramaswamy B, Sardesai SD, Noonan AM, VanDeusen JB, Malarkey WB, Kiecolt-Glaser JK. Worry and rumination in breast cancer patients: perseveration worsens self-rated health. Journal Of Behavioral Medicine 2020, 44: 253-259. PMID: 33135103, PMCID: PMC8272958, DOI: 10.1007/s10865-020-00192-9.
Surgical Management of Breast Cancer Liver MetastasisRahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.
Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatmentNaughton MJ, Salani R, Peng J, Lustberg M, DeGraffinreid C, Moon J, Loyan H, Beverly Hery CM, Paskett ED. Feasibility of implementing a text-based symptom-monitoring program of endometrial, ovarian, and breast cancer patients during treatment. Quality Of Life Research 2020, 30: 3241-3254. PMID: 33052514, PMCID: PMC8528739, DOI: 10.1007/s11136-020-02660-w.
A Human Factors Perspective to Characterize Treatment and Surgery During the COVID-19 PandemicPapautsky E, Lustberg M, Krok-Schoen J, Lee C, Park K, Attai D, Patterson E. A Human Factors Perspective to Characterize Treatment and Surgery During the COVID-19 Pandemic. Proceedings Of The International Symposium On Human Factors And Ergonomics In Health Care 2020, 9: 1-5. DOI: 10.1177/2327857920091067.
Assessment of Food Safety Knowledge and Behaviors of Cancer Patients Receiving TreatmentPaden H, Ilic S, Hatsu I, Kane K, Lustberg M, Grenade C, Bhatt A, Pardo D, Beery A. Assessment of Food Safety Knowledge and Behaviors of Cancer Patients Receiving Treatment. Journal Of The Academy Of Nutrition And Dietetics 2020, 120: a46. DOI: 10.1016/j.jand.2020.06.130.
Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancerParedes AZ, Hyer JM, Tsilimigras DI, Palmer E, Lustberg MB, Dillhoff ME, Cloyd JM, Tsung A, Ejaz A, Wells-Di Gregorio S, Pawlik TM. Association of pre-existing mental illness with all-cause and cancer-specific mortality among Medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 23: 451-458. PMID: 32843275, DOI: 10.1016/j.hpb.2020.08.002.
Abstract 5158: Estrogen receptor β agonists: A novel therapeutic strategy for breast cancerCherian M, Datta J, Kassem M, Willingham N, Manouchehri J, David J, Sheth M, Magner A, Mal R, Morgan E, VanDeusen J, Sardesai S, Williams N, Stover D, Lustberg M, Wesolowski R, Ramaswamy B, Ganju R. Abstract 5158: Estrogen receptor β agonists: A novel therapeutic strategy for breast cancer. Cancer Research 2020, 80: 5158-5158. DOI: 10.1158/1538-7445.am2020-5158.
Abstract 5514: Analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients pre- and post-neoadjuvant chemotherapy for operable breast cancerQuiroga D, Stiff A, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman R, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace T, Yu L, Duggan M, Carson W, Wesolowski R. Abstract 5514: Analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients pre- and post-neoadjuvant chemotherapy for operable breast cancer. Cancer Research 2020, 80: 5514-5514. DOI: 10.1158/1538-7445.am2020-5514.
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in miceHuang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson A, Li Y, Hong KW, DiGiacomo D, Xia S, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg M, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. Journal Of Clinical Investigation 2020, 130: 4601-4606. PMID: 32484793, PMCID: PMC7456253, DOI: 10.1172/jci136796.
Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer CenterLockwood BJ, Ntukidem OL, Ehrman SE, Schnell PM, Klemanski DL, Bhatnagar B, Lustberg M. Palliative Care Referral Patterns for Adolescent and Young Adult Patients at a Comprehensive Cancer Center. Journal Of Adolescent And Young Adult Oncology 2020, 10: 109-114. PMID: 32706607, DOI: 10.1089/jayao.2020.0081.
Palliative Care Referral Patterns of Adolescent and Young Adult Patients at a Comprehensive Cancer Center (GP725)Ehrman S, Lockwood B, Ntukidem O, Bhatnagar B, Klemanski D, Gustin J, Lustberg M. Palliative Care Referral Patterns of Adolescent and Young Adult Patients at a Comprehensive Cancer Center (GP725). Journal Of Pain And Symptom Management 2020, 60: 260. DOI: 10.1016/j.jpainsymman.2020.04.148.
Effects of Omega-3 Fatty Acids on Insulin Resistance in an Ovariectomized Mouse Model of Diet-Induced Obesity Treated with ChemotherapyOrmiston K, Zhang Z, Murphy K, DeVries A, Lustberg M, Andridge R, Orchard T. Effects of Omega-3 Fatty Acids on Insulin Resistance in an Ovariectomized Mouse Model of Diet-Induced Obesity Treated with Chemotherapy. Current Developments In Nutrition 2020, 4: nzaa044_044. PMCID: PMC7257328, DOI: 10.1093/cdn/nzaa044_044.
The Effects of Omega-3 Supplementation and Doxorubicin-Based Chemotherapy on the Murine Brain LipidomeBennouna D, Solano M, Orchard T, DeVries A, Lustberg M, Kopec R. The Effects of Omega-3 Supplementation and Doxorubicin-Based Chemotherapy on the Murine Brain Lipidome. Current Developments In Nutrition 2020, 4: nzaa044_008. PMCID: PMC7257705, DOI: 10.1093/cdn/nzaa044_008.
Associations of Long Chain Polyunsaturated Fatty Acid Biomarkers with Affective Symptoms and Cognition in Women Beginning Chemotherapy for Breast CancerZhang Z, Ormiston K, Orchard T, Lustberg M, Schnell P. Associations of Long Chain Polyunsaturated Fatty Acid Biomarkers with Affective Symptoms and Cognition in Women Beginning Chemotherapy for Breast Cancer. Current Developments In Nutrition 2020, 4: nzaa044_065. PMCID: PMC7257812, DOI: 10.1093/cdn/nzaa044_065.
Effects of Omega-3 Fatty Acids on Brain Fatty Acids and Associations with Glucose Metabolism and Anxiety-Like Behavior in an Ovariectomized Mouse Model of ChemotherapyOrmiston K, Phuwamongkolwiwat-Chu P, Fitzgerald J, Tinkai T, Lustberg M, DeVries A, Andridge R, Orchard T. Effects of Omega-3 Fatty Acids on Brain Fatty Acids and Associations with Glucose Metabolism and Anxiety-Like Behavior in an Ovariectomized Mouse Model of Chemotherapy. Current Developments In Nutrition 2020, 4: nzaa057_044. PMCID: PMC7257389, DOI: 10.1093/cdn/nzaa057_044.
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).Okines A, Paplomata E, Wahl T, Wright G, Sutherland S, Jakobsen E, Valdes F, Chan A, Clark A, Conlin A, Lustberg M, Specht J, Pluard T, Zhu X, Krop I, Gelmon K, Slamon D, Ramos J, An G, Hamilton E. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1043-1043. DOI: 10.1200/jco.2020.38.15_suppl.1043.
Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients.Johns K, Kalister S, Mwandha N, Adams E, Basinger H, Fugett S, Crawford D, Draime M, Shinde N, Kassem M, Radcliff L, Unthank B, Cherian M, Sardesai S, Stover D, Vandeusen J, Wesolowski R, Williams N, Ramaswamy B, Lustberg M. Applying the Collaborative Care Model to treat depression and anxiety in breast cancer (BC) patients. Journal Of Clinical Oncology 2020, 38: e14004-e14004. DOI: 10.1200/jco.2020.38.15_suppl.e14004.
PROMIS-10 scores at six months post-baseline among breast and gynecologic oncology patients participating in a text-based symptom monitoring program with patient navigation.Naughton M, Salani R, Lustberg M, Peng J, Moon J, Loyan H, Paskett E. PROMIS-10 scores at six months post-baseline among breast and gynecologic oncology patients participating in a text-based symptom monitoring program with patient navigation. Journal Of Clinical Oncology 2020, 38: e19173-e19173. DOI: 10.1200/jco.2020.38.15_suppl.e19173.
Clinician perspectives of complementary and integrative medicine (CIM) at an academic cancer center.Husain M, Rogers S, Klemanski D, Fullmer M, Hreachmack C, Kemper K, Stephens J, Desai P, Lustberg M. Clinician perspectives of complementary and integrative medicine (CIM) at an academic cancer center. Journal Of Clinical Oncology 2020, 38: e24047-e24047. DOI: 10.1200/jco.2020.38.15_suppl.e24047.
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.Noonan A, Lustberg M, Schnell P, Hays J, Jin N, Abushahin L, Malalur P, Roychowdhury S, Elkhatib R, Chen H, Al Mutar S, Sparreboom A, Hu S. A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab. Journal Of Clinical Oncology 2020, 38: tps12125-tps12125. DOI: 10.1200/jco.2020.38.15_suppl.tps12125.
A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer.Adams E, Lustberg M, Jin Y, Li Y, Sparreboom A, Hu S. A phase Ib study of the safety and pharmacology of nilotinib to prevent paclitaxel-induced peripheral neuropathy in patients with breast cancer. Journal Of Clinical Oncology 2020, 38: tps12128-tps12128. DOI: 10.1200/jco.2020.38.15_suppl.tps12128.
Primary care physician’s confidence and coordination regarding the survivorship care for older breast cancer survivorsStephens C, Klemanski D, Lustberg MB, Noonan AM, Brill S, Krok-Schoen JL. Primary care physician’s confidence and coordination regarding the survivorship care for older breast cancer survivors. Supportive Care In Cancer 2020, 29: 223-230. PMID: 32338315, DOI: 10.1007/s00520-020-05448-3.
Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral NeurotoxicityHuang K, Leblanc A, Alberti P, Sprowl J, Wang J, Lustberg M, Cavaletti G, Hu S, Sparreboom A. Differential Contribution of Neuronal Uptake Transporters to Oxaliplatin Peripheral Neurotoxicity. The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.03083.
Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic CancerParedes AZ, Hyer JM, Palmer E, Lustberg MB, Pawlik TM. Racial/Ethnic Disparities in Hospice Utilization Among Medicare Beneficiaries Dying from Pancreatic Cancer. Journal Of Gastrointestinal Surgery 2020, 25: 155-161. PMID: 32193849, DOI: 10.1007/s11605-020-04568-9.
Abstract P2-13-06: Living well with advanced breast cancer: A unique multidisciplinary clinic designed to empower and educate patients with metastatic breast cancer (MBC)Ramaswamy B, Reinbolt R, Basinger H, Radcliff L, Unthank B, Hauck K, Hoffman K, Borja N, Pedraza S, Holley E, Ntukidem L, Cherian M, Noonan A, Sardesai S, Stover D, VanDeusen J, Williams N, Wesolowski R, Lustberg M. Abstract P2-13-06: Living well with advanced breast cancer: A unique multidisciplinary clinic designed to empower and educate patients with metastatic breast cancer (MBC). Cancer Research 2020, 80: p2-13-06-p2-13-06. DOI: 10.1158/1538-7445.sabcs19-p2-13-06.
Abstract P5-10-03: Perceptions of somatic genomic testing in patients with metastatic breast cancer: Psychosocial factors, emotional well-being, and genetic comprehensionAdams E, Asad S, Abdel-Rasoul M, Reinbolt R, Wesolowski R, Tolliver K, Gillespie S, Collier K, Noonan A, Sardesai S, VanDeusen J, Williams N, Shapiro C, Macre E, Ramaswamy B, Lee C, Lustberg M, Stover D. Abstract P5-10-03: Perceptions of somatic genomic testing in patients with metastatic breast cancer: Psychosocial factors, emotional well-being, and genetic comprehension. Cancer Research 2020, 80: p5-10-03-p5-10-03. DOI: 10.1158/1538-7445.sabcs19-p5-10-03.
Abstract P2-20-07: Assessment of leptomeningeal carcinomatosis management and outcomes in patients with advanced breast cancer from 2005 to 2015: A single institution experienceRinehardt H, Williams N, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Eibl P, Suresh A, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, VanDeusen J, Bazan J, Ramswamy B, Noonan A. Abstract P2-20-07: Assessment of leptomeningeal carcinomatosis management and outcomes in patients with advanced breast cancer from 2005 to 2015: A single institution experience. Cancer Research 2020, 80: p2-20-07-p2-20-07. DOI: 10.1158/1538-7445.sabcs19-p2-20-07.
Chemotherapy-induced peripheral neuropathy: ice, compression, both, or neither?Loprinzi C, Lustberg M, Hershman D, Ruddy K. Chemotherapy-induced peripheral neuropathy: ice, compression, both, or neither? Annals Of Oncology 2020, 31: 5-6. PMID: 31912795, DOI: 10.1016/j.annonc.2019.10.009.
Association of pre-existing mental illness with all-cause and cancer-specific mortality in medicare beneficiaries with pancreatic cancerParedes A, Hyer J, Palmer E, Lustberg M, Dillhoff M, Ejaz A, Bean J, Cloyd J, Tsung A, Pawlik T. Association of pre-existing mental illness with all-cause and cancer-specific mortality in medicare beneficiaries with pancreatic cancer. Hepato Pancreato Biliary 2020, 22: s148-s149. DOI: 10.1016/j.hpb.2020.04.678.
Racial/ethnic disparities in hospice utilization among Medicare beneficiaries dying from pancreatic cancer.Paredes A, Hyer M, Palmer E, Lustberg M, Pawlik T. Racial/ethnic disparities in hospice utilization among Medicare beneficiaries dying from pancreatic cancer. Journal Of Clinical Oncology 2019, 37: 41-41. DOI: 10.1200/jco.2019.37.31_suppl.41.
Palliative care referral patterns of adolescent and young adult patients at a comprehensive cancer center.Lockwood B, Ntukidem O, Ehrman S, Lustberg M, Bhatnagar B, Klemanski D. Palliative care referral patterns of adolescent and young adult patients at a comprehensive cancer center. Journal Of Clinical Oncology 2019, 37: 63-63. DOI: 10.1200/jco.2019.37.31_suppl.63.
350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)Wesolowski R, Brufsky A, Chambers M, Bhattacharya S, Lustberg M, VanDeusen J, Sardesai S, Williams N, Noonan A, Phelps M, Grever M, Stephens J, Carson W, Ramaswamy B. 350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173). Annals Of Oncology 2019, 30: v126. DOI: 10.1093/annonc/mdz242.045.
Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacyWorthen-Chaudhari L, Lamantia M, Monfort S, Mysiw W, Chaudhari A, Lustberg M. Partnered, adapted argentine tango dance for cancer survivors: A feasibility study and pilot study of efficacy. Clinical Biomechanics 2019, 70: 257-264. PMID: 31751861, DOI: 10.1016/j.clinbiomech.2019.08.010.
LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITYWilliams N, Rinehardt H, Morgan E, Kassem M, Palettas M, Puduvalli V, Giglo P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY. Neuro-Oncology Advances 2019, 1: i8-i8. PMCID: PMC7213376, DOI: 10.1093/noajnl/vdz014.033.
Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumorsBekaii-Saab T, Wei L, Wesolowski R, Ahn D, Wu C, Lustberg M, Mortazavi A, Ramaswamy B, Overholser J, Kaumaya P. Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors. 2019, ct017-ct017. DOI: 10.1158/1538-7445.sabcs18-ct017.
Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumorsBekaii-Saab T, Wei L, Wesolowski R, Ahn D, Wu C, Lustberg M, Mortazavi A, Ramaswamy B, Overholser J, Kaumaya P. Abstract CT017: A Phase Ib of a combination of two chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B cell peptide vaccine emulsified in ISA 720 and nor-MDP adjuvant in patients with advanced solid tumors. Cancer Research 2019, 79: ct017-ct017. DOI: 10.1158/1538-7445.am2019-ct017.
Oncologists' Perceptions of a Digital Tool to Improve Cancer Survivors' Cardiovascular HealthKelley M, Foraker R, Lin E, Kulkarni M, Lustberg M, Weaver K. Oncologists' Perceptions of a Digital Tool to Improve Cancer Survivors' Cardiovascular Health. ACI Open 2019, 03: e78-e87. DOI: 10.1055/s-0039-1696732.
An omega-3 Fatty Acid Enriched Diet Reduces Anxiety-like Behavior While High Dietary Sucrose During Chemotherapy Increases Anxiety-like Behavior in Mice (P14-023-19)Ormiston K, Orchard T, DeVries A, Phuwamongkolwiwat P, Li J, Andridge R, Fitzgerald J, Tinkai T, Lustberg M. An omega-3 Fatty Acid Enriched Diet Reduces Anxiety-like Behavior While High Dietary Sucrose During Chemotherapy Increases Anxiety-like Behavior in Mice (P14-023-19). Current Developments In Nutrition 2019, 3: nzz052.p14-023-19. PMCID: PMC6573952, DOI: 10.1093/cdn/nzz052.p14-023-19.
Inflammatory and Affective Responses to Acute Resistance Exercise of Varying Loads in Postmenopausal Women.Fairman C, Lustberg M, Haynam M, Kimborowicz A, Bartels J, Lantz M, Johnson S, Maresh C, Kraemer W, Focht B. Inflammatory and Affective Responses to Acute Resistance Exercise of Varying Loads in Postmenopausal Women. Medicine & Science In Sports & Exercise 2019, 51: 881-881. DOI: 10.1249/01.mss.0000563132.59377.b8.
Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.
Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University.Rinehardt H, Morgan E, Kassem M, Palettas M, Miah A, Alnahhas I, Guillermo Prieto Eibl P, Suresh A, Ganju A, Williams N, Puduvalli V, Giglio P, Lustberg M, Wesolowski R, Sardesai S, Stover D, Vandeusen J, Bazan J, Ramaswamy B, Noonan A. Assessment of Leptomeningeal Carcinomatosis Diagnosis and Outcomes from 2005 to 2015 at Ohio State University. Journal Of Clinical Oncology 2019, 37: e13554-e13554. DOI: 10.1200/jco.2019.37.15_suppl.e13554.
The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN).Lustberg M, Pfeiffer P, Qvortrup C, Muro K, Bengtson M, Nittve M, Sonesson C, Nagahama F, Sonehara Y, Carlsson C. The Global POLAR program: Two pivotal placebo-controlled studies of calmangafodipir used on top of modified FOLFOX6 to prevent chemotherapy-induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps3616-tps3616. DOI: 10.1200/jco.2019.37.15_suppl.tps3616.
CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution ExperienceBoutrid H, Lustberg M, Vandeusen J, Sardesai S, Stover D, Wesolowski R, Cherian M, Stephens J, Palettas M, Morgan E, Kassem M, Berger M, Vargo C, Ramaswamy B, Williams N. CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience. Journal Of The National Comprehensive Cancer Network 2019, 17: clo19-027. DOI: 10.6004/jnccn.2018.7251.
REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGSAddison D, Bonsu J, Charles L, Guha A, Baker B, Woyach J, Awan F, Rogers K, Lustberg M, Reinbolt R, Brammer J, Miller E, Jneid H, Paskett E. REPORTING OF CARDIOVASCULAR EVENTS IN CLINICAL TRIALS SUPPORTING FDA-APPROVAL OF CONTEMPORARY CANCER DRUGS. Journal Of The American College Of Cardiology 2019, 73: 1879. DOI: 10.1016/s0735-1097(19)32485-4.
Abstract P3-07-08: Multi-omic predictor of rapid and late relapse in primary triple negative breast cancerZhang Y, Nock W, Asad S, Adams E, Singh J, Damicis A, Lustberg M, Noonan A, Reinbolt R, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Ramaswamy B, Stover D. Abstract P3-07-08: Multi-omic predictor of rapid and late relapse in primary triple negative breast cancer. Cancer Research 2019, 79: p3-07-08-p3-07-08. DOI: 10.1158/1538-7445.sabcs18-p3-07-08.
Abstract P4-14-12: Outcomes in hormone receptor positive, invasive lobular cancer in the era of endocrine monotherapyWilliams N, Liu J, Stephens J, Palettas M, Boutrid H, Sardesai S, Reinbolt R, Stover D, VanDeusen J, Noonan A, Wesolowski R, Lustberg M, Ramaswamy B. Abstract P4-14-12: Outcomes in hormone receptor positive, invasive lobular cancer in the era of endocrine monotherapy. Cancer Research 2019, 79: p4-14-12-p4-14-12. DOI: 10.1158/1538-7445.sabcs18-p4-14-12.
Abstract P4-16-03: Cardiovascular outcomes and long term survival with discontinuation of adjuvant trastuzumabSardesai S, Liu J, Palettas M, Stephens J, Stover D, Williams N, Reinbolt R, VanDeusen J, Wesolowski R, Lustberg M, Ramaswamy B. Abstract P4-16-03: Cardiovascular outcomes and long term survival with discontinuation of adjuvant trastuzumab. Cancer Research 2019, 79: p4-16-03-p4-16-03. DOI: 10.1158/1538-7445.sabcs18-p4-16-03.
Abstract P1-09-01: CD8+ T-cell gene expression and signatures in breast cancer and adjacent normal breast tissue: Association with body mass index, alcohol intake, and age at diagnosisDamicis A, Heng Y, Kensler K, Asad S, Adams E, Singh J, Zhang Y, Nock W, Wesolowski R, Williams N, Reinbolt R, Sardesai S, VanDeusen J, Noonan A, Lustberg M, Ramaswamy B, Eliassen A, Hankinson S, Tamimi R, Stover D. Abstract P1-09-01: CD8+ T-cell gene expression and signatures in breast cancer and adjacent normal breast tissue: Association with body mass index, alcohol intake, and age at diagnosis. Cancer Research 2019, 79: p1-09-01-p1-09-01. DOI: 10.1158/1538-7445.sabcs18-p1-09-01.
The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).Pfeiffer P, Qvortrup C, Muro K, Lustberg M, Nagahama F, Sonehara Y, Bengtson M, Nittve M, Sonesson C, Carlsson C. The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). Journal Of Clinical Oncology 2019, 37: tps722-tps722. DOI: 10.1200/jco.2019.37.4_suppl.tps722.
Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based ChemotherapyOrchard T, Gaudier-Diaz M, Phuwamongkolwiwat-Chu P, Andridge R, Lustberg M, Bomser J, Cole R, Belury M, DeVries A. Low Sucrose, Omega-3 Enriched Diet Has Region-Specific Effects on Neuroinflammation and Synaptic Function Markers in a Mouse Model of Doxorubicin-Based Chemotherapy. Nutrients 2018, 10: 2004. PMID: 30567351, PMCID: PMC6316589, DOI: 10.3390/nu10122004.
Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC).Quick A, Zvinovski F, Hudson C, Hundley A, Evans C, Suresh A, Stephens J, Carpenter K, Ramaswamy B, Reinbolt R, Noonan A, VanDeusen J, Wesolowski R, Stover D, Williams N, Sardesai S, Smith K, Faubion S, Loprinzi C, Lustberg M. Fractional CO2 laser therapy for genitourinary syndrome of menopause (GSM) in survivors of breast cancer (BC). Journal Of Clinical Oncology 2018, 36: 202-202. DOI: 10.1200/jco.2018.36.34_suppl.202.
Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding PracticesGanju A, Suresh A, Stephens J, Palettas M, Burke D, Miles L, Lehman K, Rudesill R, Lustberg M, Bose-Brill S, Ramaswamy B. Learning, Life, and Lactation: Knowledge of Breastfeeding's Impact on Breast Cancer Risk Reduction and Its Influence on Breastfeeding Practices. Breastfeeding Medicine 2018, 13: 651-656. PMID: 30354228, DOI: 10.1089/bfm.2018.0170.
PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancerHou Y, Nitta H, Wei L, Banks P, Lustberg M, Wesolowski R, Ramaswamy B, Parwani A, Li Z. PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer. The Breast Journal 2018, 24: 911-919. PMID: 30230111, PMCID: PMC6724200, DOI: 10.1111/tbj.13112.
An Evaluation of Factors Predicting Diet Quality among Cancer PatientsKane K, Ilic S, Paden H, Lustberg M, Grenade C, Bhatt A, Diaz D, Beery A, Hatsu I. An Evaluation of Factors Predicting Diet Quality among Cancer Patients. Nutrients 2018, 10: 1019. PMID: 30081543, PMCID: PMC6116020, DOI: 10.3390/nu10081019.
Abstract A20: Analysis of tumor infiltrating lymphocytes and expression of PD1 and PD-L1 in breast tumors prior to and after neoadjuvant chemotherapyWesolowski R, Li Z, McQuinn C, Lustberg M, Ramaswamy B, Noonan A, Reinbolt R, Sardesai S, VanDeusen J, Williams N, Carson W. Abstract A20: Analysis of tumor infiltrating lymphocytes and expression of PD1 and PD-L1 in breast tumors prior to and after neoadjuvant chemotherapy. Molecular Cancer Research 2018, 16: a20-a20. DOI: 10.1158/1557-3125.advbc17-a20.
Abstract A55: A prospective geriatric breast cancer cohort study to define unique features and outcomes in older breast cancer patientsNoonan A, Overcash J, Suresh A, Flora L, Stephens J, Bhatt G, Reinbolt R, Williams N, Wesolowski R, VanDeusen J, Sardesai S, Lustberg M, Ramaswamy B. Abstract A55: A prospective geriatric breast cancer cohort study to define unique features and outcomes in older breast cancer patients. Molecular Cancer Research 2018, 16: a55-a55. DOI: 10.1158/1557-3125.advbc17-a55.
Abstract C57: Knowledge of breastfeeding to reduce breast cancer riskGanju A, Suresh A, Stephens J, Palettas M, Burke D, Miles L, Lustberg M, Brill S, Ramaswamy B. Abstract C57: Knowledge of breastfeeding to reduce breast cancer risk. Cancer Epidemiology Biomarkers & Prevention 2018, 27: c57-c57. DOI: 10.1158/1538-7755.disp17-c57.
Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health InitiativeKrok-Schoen J, Brasky T, Hunt R, Rohan T, Baker T, Li W, Carbone L, Mackey R, Snetselaar L, Lustberg M, Neuhouser M. Dietary Long-Chain n-3 Fatty Acid Intake and Arthritis Risk in the Women’s Health Initiative. Journal Of The Academy Of Nutrition And Dietetics 2018, 118: 2057-2069. PMID: 29921541, PMCID: PMC6204099, DOI: 10.1016/j.jand.2018.04.005.
A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast CancerBorniger J, Walker W, Surbhi, Emmer K, Zhang N, Zalenski A, Muscarella S, Fitzgerald J, Smith A, Braam C, TinKai T, Magalang U, Lustberg M, Nelson R, DeVries A. A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. Cell Metabolism 2018, 28: 118-129.e5. PMID: 29805100, PMCID: PMC6031468, DOI: 10.1016/j.cmet.2018.04.021.
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.Saito Y, Li Z, Lustberg M, Grenade C, Wesolowski R. Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. Cancer Treatment And Research Communications 2018, 16: 9-12. PMID: 31299005, DOI: 10.1016/j.ctarc.2018.04.001.
Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white womenFoy K, Fisher J, Lustberg M, Gray D, DeGraffinreid C, Paskett E. Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women. Npj Breast Cancer 2018, 4: 7. PMID: 29582015, PMCID: PMC5861087, DOI: 10.1038/s41523-018-0059-5.
Strategic planning for implementation of Commission on Cancer standard 3.3 in a tertiary academic center.Klemanski D, Scharschmidt T, Ramirez M, Browning K, Ghosh-Berkebile R, Hatfield R, Schimming D, Lustberg M. Strategic planning for implementation of Commission on Cancer standard 3.3 in a tertiary academic center. Journal Of Clinical Oncology 2018, 36: 58-58. DOI: 10.1200/jco.2018.36.7_suppl.58.
Implementing Liquid Biopsies in Clinical TrialsLustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.
Abstract OT2-05-03: Does minocycline mitigate chemotherapy induced neuroinflammation? A phase II randomized placebo controlled studyBoutrid H, Reinbolt R, Knopp M, Williams N, VanDeusen J, Sardesai S, Noonan A, Flora L, Gleich E, Pan X, Berger M, Vargo C, Wesolowski R, Ramaswamy B, DeVries A, Lustberg M. Abstract OT2-05-03: Does minocycline mitigate chemotherapy induced neuroinflammation? A phase II randomized placebo controlled study. Cancer Research 2018, 78: ot2-05-03-ot2-05-03. DOI: 10.1158/1538-7445.sabcs17-ot2-05-03.
OATP1B2 deficiency protects against paclitaxel-induced neurotoxicityLeblanc A, Sprowl J, Alberti P, Chiorazzi A, Arnold W, Gibson A, Hong K, Pioso M, Chen M, Huang K, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen R, Reinbolt R, Lustberg M, Sucheston-Campbell L, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal Of Clinical Investigation 2018, 128: 816-825. PMID: 29337310, PMCID: PMC5785270, DOI: 10.1172/jci96160.
Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac DysfunctionMilks M, Velez M, Mehta N, Ishola A, Van Houten T, Yildiz V, Reinbolt R, Lustberg M, Smith S, Orsinelli D. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction. The American Journal Of Cardiology 2018, 121: 867-873. PMID: 29454478, DOI: 10.1016/j.amjcard.2017.12.022.
Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study DataOrchard T, Andridge R, Yee L, Lustberg M. Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. Journal Of The Academy Of Nutrition And Dietetics 2017, 118: 578-588.e1. PMID: 29233615, PMCID: PMC5869134, DOI: 10.1016/j.jand.2017.09.024.
Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithmReinbolt R, Sonis S, Timmers C, Fernández‐Martínez J, Cernea A, Andrés‐Galiana E, Hashemi S, Miller K, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor‐related arthralgia in patients with breast cancer using a novel machine‐learning algorithm. Cancer Medicine 2017, 7: 240-253. PMID: 29168353, PMCID: PMC5773952, DOI: 10.1002/cam4.1256.
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal painLustberg M, Orchard T, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro C, Yee L. Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Research And Treatment 2017, 167: 709-718. PMID: 29101597, PMCID: PMC5809189, DOI: 10.1007/s10549-017-4559-z.
Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood SamplesMiller B, Lustberg M, Summers T, Chalmers J. Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. 2017, 1634: 219-234. PMID: 28819855, DOI: 10.1007/978-1-4939-7144-2_19.
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancerWesolowski R, Duggan M, Stiff A, Markowitz J, Trikha P, Levine K, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Reinbolt R, Mrozek E, Byrd J, Caligiuri M, Mace T, Carson W. Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunology, Immunotherapy 2017, 66: 1437-1447. PMID: 28688082, PMCID: PMC5647220, DOI: 10.1007/s00262-017-2038-3.
THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanismYoung N, Thomas E, Snoad B, Sharma J, Mobeen M, DeVries A, Bratasz A, Lustberg M, Jarjour W, Reinbolt R. THU0062 Novel animal model of aromatase inhibitor-induced arthralgia suggests an estrogen-independent inflammatory mechanism. Annals Of The Rheumatic Diseases 2017, 76: 222. DOI: 10.1136/annrheumdis-2017-eular.5424.
Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA).Reinbolt R, Sonis S, Timmers C, Fernández-Martínez J, deAndrés-Galiana E, Hashemi S, Miller K, Ramaswamy B, Wesolowski R, Noonan A, Dewani S, Williams N, Sardesai S, Pilarski R, Lustberg M. Genomic risk prediction of aromatase inhibitor-related arthralgias (AIA) in breast cancer (BC) patients using a novel analytical algorithm (NAA). Journal Of Clinical Oncology 2017, 35: 10102-10102. DOI: 10.1200/jco.2017.35.15_suppl.10102.
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.
Effect of an Argentine Tango Intervention on Gait Variability in Cancer SurvivorsChaudhari A, Monfort S, Lamantia M, Lustberg M, Worthen-Chaudhari L. Effect of an Argentine Tango Intervention on Gait Variability in Cancer Survivors. Medicine & Science In Sports & Exercise 2017, 49: 675. DOI: 10.1249/01.mss.0000518781.78765.09.
Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patientsMonfort S, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton M, Loprinzi C, Chaudhari A, Lustberg M. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Research And Treatment 2017, 164: 69-77. PMID: 28374323, PMCID: PMC5510549, DOI: 10.1007/s10549-017-4230-8.
Effect of chemotherapy-induced peripheral neuropathy on postural control in cancer survivors.Herman H, Monfort S, Pan X, Chaudhari A, Lustberg M. Effect of chemotherapy-induced peripheral neuropathy on postural control in cancer survivors. Journal Of Clinical Oncology 2017, 35: 128-128. DOI: 10.1200/jco.2017.35.5_suppl.128.
Pleiotropic effects of nutritional ketosis: Conceptual framework for keto-adaptation as a breast cancer therapyHyde P, Lustberg M, Miller V, LaFountain R, Volek J. Pleiotropic effects of nutritional ketosis: Conceptual framework for keto-adaptation as a breast cancer therapy. Cancer Treatment And Research Communications 2017, 12: 32-39. DOI: 10.1016/j.ctarc.2017.06.001.
Longitudinal Biomechanical Assessment of Arts-Based Balance Interventions for Elderly at Risk of Falling: A 9-month Case StudyWorthen-Chaudhari L, Lamantia M, Bland C, Monfort S, Chaudhari A, Lustberg M, Mysiw W. Longitudinal Biomechanical Assessment of Arts-Based Balance Interventions for Elderly at Risk of Falling: A 9-month Case Study. Archives Of Physical Medicine And Rehabilitation 2016, 97: e15-e16. DOI: 10.1016/j.apmr.2016.09.041.
Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical AnalysisWu Y, Park K, Deighan C, Amaya P, Miller B, Pan Q, Zborowski M, Lustberg M, Chalmers J. Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis. Frontiers In Oncology 2016, 6: 234. PMID: 27878106, PMCID: PMC5099140, DOI: 10.3389/fonc.2016.00234.
Novel Balance Interventions for Chemotherapy-Induced Peripheral Neuropathy: Argentine TangoWorthen-Chaudhari L, Lamantia M, Monfort S, Chaudhari A, Lustberg M. Novel Balance Interventions for Chemotherapy-Induced Peripheral Neuropathy: Argentine Tango. Archives Of Physical Medicine And Rehabilitation 2016, 97: e119. DOI: 10.1016/j.apmr.2016.08.372.
Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancerHimmel L, Lustberg M, DeVries A, Poi M, Chen C, Kulp S. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental And Toxicologic Pathology 2016, 68: 505-515. PMID: 27555377, PMCID: PMC5203928, DOI: 10.1016/j.etp.2016.08.001.
Anthracycline CardiotoxicityLustberg M, Zareba K. Anthracycline Cardiotoxicity. Circulation Cardiovascular Imaging 2016, 9: e005324. PMID: 27502063, DOI: 10.1161/circimaging.116.005324.
Abstract CT033: Phase 1b study of heat shock protein 90 inhibitor onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173)Wesolowski R, Lustberg M, Mrozek E, Layman R, Reinbolt R, Poi M, Osman N, Lively A, Stephens J, Grever M, Ramaswamy B. Abstract CT033: Phase 1b study of heat shock protein 90 inhibitor onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Cancer Research 2016, 76: ct033-ct033. DOI: 10.1158/1538-7445.am2016-ct033.
Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancerRamaswamy B, Mrozek E, Lustberg M, Wesolowski R, Layman R, Abdel-Rasoul M, Timmers C, Patrick R, Sexton J, Macrae E, Shapiro C, Budd T, Harris L, Isaacs C, Ismail-Khan R, Dees C, Poklepovic A, Grever M, Chen H, Villalona M, Carson W. Abstract LB-216: NCI 9455: Phase II study of trametinib followed by trametinib plus AKT inhibitor,GSK2141795 in patients with advanced triple negative breast cancer. Cancer Research 2016, 76: lb-216-lb-216. DOI: 10.1158/1538-7445.am2016-lb-216.
Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot studyMonfort S, Pan X, Patrick R, Singaravelu J, Loprinzi C, Lustberg M, Chaudhari A. Natural history of postural instability in breast cancer patients treated with taxane-based chemotherapy: A pilot study. Gait & Posture 2016, 48: 237-242. PMID: 27341530, PMCID: PMC4969166, DOI: 10.1016/j.gaitpost.2016.06.011.
TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancerElbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser M, Shilo K, Ganju R. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget 2016, 9: 33459-33470. PMID: 30323891, PMCID: PMC6173360, DOI: 10.18632/oncotarget.9663.
Breast cancer and social environment: getting by with a little help from our friendsHinzey A, Gaudier-Diaz M, Lustberg M, DeVries A. Breast cancer and social environment: getting by with a little help from our friends. Breast Cancer Research 2016, 18: 54. PMID: 27225892, PMCID: PMC4881170, DOI: 10.1186/s13058-016-0700-x.
Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients.Monfort S, Pan X, Patrick R, Singaravelu J, Layman R, Mrozek E, Ramaswamy B, Reinbolt R, Wesolowski R, Naughton M, Shapiro C, Loprinzi C, Chaudhari A, Lustberg M. Longitudinal changes in patient-reported symptoms and physical function during taxane-based chemotherapy in breast cancer patients. Journal Of Clinical Oncology 2016, 34: 10098-10098. DOI: 10.1200/jco.2016.34.15_suppl.10098.
Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study.Reinbolt R, Tolliver K, Abdel-Rasoul M, Timmers C, Ramaswamy B, Layman R, Wesolowski R, Mrozek E, Gillespie S, Chen J, Ali S, Balasubramanian S, Shapiro C, Ostrowski M, Leone G, Macrae E, Lustberg M. Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study. Journal Of Clinical Oncology 2016, 34: 11578-11578. DOI: 10.1200/jco.2016.34.15_suppl.11578.
Metaplastic progression free survival compared to triple negative breast cancer, a retrospective analysis.Lustberg M, Luff A, Young G, Layman R, Mrozek E, Reinbolt R, Wesolowski R, Ramaswamy B. Metaplastic progression free survival compared to triple negative breast cancer, a retrospective analysis. Journal Of Clinical Oncology 2016, 34: e12552-e12552. DOI: 10.1200/jco.2016.34.15_suppl.e12552.
Effects of exercise interventions during different treatments in breast cancer.Fairman C, Focht B, Lucas A, Lustberg M. Effects of exercise interventions during different treatments in breast cancer. The Journal Of Community And Supportive Oncology 2016, 14: 200-9. PMID: 27258052, PMCID: PMC5522734, DOI: 10.12788/jcso.0225.
Depletion of Normal Cells for CTC EnrichmentChalmers J, Lustberg M, Deighan C, Park K, Wu Y, Amaya P. Depletion of Normal Cells for CTC Enrichment. 2016, 301-312. DOI: 10.1002/9781119244554.ch14.
Abstract P4-09-18: Characterization of circulating myeloid derived suppressor cells and cytokines in patients undergoing neo-adjuvant chemotherapy for breast cancerWesolowski R, Duggan M, Stiff A, Trikha P, Schoenfield L, Abdel-Rasoul M, Layman R, Ramaswamy B, Macrae E, Lustberg M, Mrozek E, Carson W. Abstract P4-09-18: Characterization of circulating myeloid derived suppressor cells and cytokines in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Research 2016, 76: p4-09-18-p4-09-18. DOI: 10.1158/1538-7445.sabcs15-p4-09-18.
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination RepairVillalona-Calero M, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal Of The National Cancer Institute 2016, 108: djv437. PMID: 26848151, PMCID: PMC4948564, DOI: 10.1093/jnci/djv437.
Risk factors for anthracycline-associated cardiotoxicityReinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer 2015, 24: 2173-2180. PMID: 26563179, PMCID: PMC4874738, DOI: 10.1007/s00520-015-3008-y.
Effects of chemotherapy on quality of life in breast cancer survivors.Wandell K, Lustberg M, Reinbolt R, Orchard T, Andridge R, Wandell H, Schade C, Moran T, Yang N, Conlan T. Effects of chemotherapy on quality of life in breast cancer survivors. Journal Of Clinical Oncology 2015, 33: 112-112. DOI: 10.1200/jco.2015.33.28_suppl.112.
Impact of breast cancer treatment on body mass index (BMI) over time.Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primaryMikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.
A Novel Dietary Intervention to Reduce Chronic Inflammation in Postmenopausal WomenArnold K, Gunther C, Lustberg M, Andridge R, Orchard T. A Novel Dietary Intervention to Reduce Chronic Inflammation in Postmenopausal Women. Journal Of The Academy Of Nutrition And Dietetics 2015, 115: a55. DOI: 10.1016/j.jand.2015.06.193.
Effects of Sucrose and Omega-3 Fatty Acids on Chemotherapy-Induced Neuroinflammation in a Mouse Model of Breast CancerGaudier-Diaz M, Lustberg M, Cole R, Belury M, DeVries A, Orchard T. Effects of Sucrose and Omega-3 Fatty Acids on Chemotherapy-Induced Neuroinflammation in a Mouse Model of Breast Cancer. Journal Of The Academy Of Nutrition And Dietetics 2015, 115: a25. DOI: 10.1016/j.jand.2015.06.081.
PalbociclibMangini N, Wesolowski R, Ramaswamy B, Lustberg M, Berger M. Palbociclib. Annals Of Pharmacotherapy 2015, 49: 1252-1260. PMID: 26324355, PMCID: PMC7331461, DOI: 10.1177/1060028015602273.
Abstract 4786: Cellular localization of PRMT5 correlates with poor recurrent free survival in triple-negative breast cancer (TNBC)Alexander E, Earl C, Mo X, Shilo K, Baiocchi R, Lustberg M. Abstract 4786: Cellular localization of PRMT5 correlates with poor recurrent free survival in triple-negative breast cancer (TNBC). 2015, 4786-4786. DOI: 10.1158/1538-7445.am2015-4786.
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cellsOliveira-Costa J, de Carvalho A, da Silveira G, Amaya P, Wu Y, Park K, Gigliola M, Lustberg M, Buim M, Ferreira E, Kowalski L, Chalmers J, Soares F, Carraro D, Ribeiro-Silva A. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015, 6: 20902-20920. PMID: 26041877, PMCID: PMC4673238, DOI: 10.18632/oncotarget.3939.
Abstract P1-09-03: Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot studyLustberg M, Orchard T, Pan X, Reinbolt R, Logan A, Lester J, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Berger M, Knopp M, Loprinzi C, Shapiro C, Yee L. Abstract P1-09-03: Prevention of aromatase Inhibitor (AI)-induced joint symptoms with omega-3 fatty acid supplementation: A randomized placebo-controlled pilot study. 2015, p1-09-03-p1-09-03. DOI: 10.1158/1538-7445.sabcs14-p1-09-03.
Abstract P1-09-04: Longitudinal evaluation of taxane-induced neuropathy in early stage breast cancerLustberg M, Monfort S, Singaravelu J, Reinbolt R, Pan X, Ramaswamy B, Layman R, Wesolowski R, Mrozek E, Macrae E, Shapiro C, Patrick R, Loprinzi C, Chaudhari A. Abstract P1-09-04: Longitudinal evaluation of taxane-induced neuropathy in early stage breast cancer. 2015, p1-09-04-p1-09-04. DOI: 10.1158/1538-7445.sabcs14-p1-09-04.
Abstract P1-09-30: Relationship of dietary and red blood cell polyunsaturated fatty acids to inflammatory markers in breast cancer survivors taking aromatase inhibitorsOrchard T, Pan X, Lester J, Logan A, Shapiro C, Jackson R, Belury M, Yee L, Lustberg M. Abstract P1-09-30: Relationship of dietary and red blood cell polyunsaturated fatty acids to inflammatory markers in breast cancer survivors taking aromatase inhibitors. 2015, p1-09-30-p1-09-30. DOI: 10.1158/1538-7445.sabcs14-p1-09-30.
Abstract P2-03-03: Incidence of actionable genomic alterations in metastatic breast cancer: A prospective studyReinbolt R, Tolliver K, Abdel-Rasoul M, Timmers C, Ramaswamy B, Layman R, Wesolowski R, Lustberg M, Mrozek E, Ottman S, Chen J, Shapiro C, Ostrowski M, Leone G, Macrae E. Abstract P2-03-03: Incidence of actionable genomic alterations in metastatic breast cancer: A prospective study. 2015, p2-03-03-p2-03-03. DOI: 10.1158/1538-7445.sabcs14-p2-03-03.
Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer SurvivorsArnold K, Andridge R, Logan A, Yee L, Lustberg M, Orchard T. Healthy Eating Index Scores are Associated with Inflammatory Markers in Breast Cancer Survivors. The FASEB Journal 2015, 29 DOI: 10.1096/fasebj.29.1_supplement.lb267.
Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship IssueLester J, Pahouja G, Andersen B, Lustberg M. Atrophic Vaginitis in Breast Cancer Survivors: A Difficult Survivorship Issue. Journal Of Personalized Medicine 2015, 5: 50-66. PMID: 25815692, PMCID: PMC4493485, DOI: 10.3390/jpm5020050.
Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical TrialsHicks M, Macrae E, Abdel‐Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Neoadjuvant Dual HER2‐Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2‐Positive Breast Cancer: A Meta‐Analysis of Randomized Prospective Clinical Trials. The Oncologist 2015, 20: 337-343. PMID: 25732265, PMCID: PMC4391765, DOI: 10.1634/theoncologist.2014-0334.
Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic ApproachReinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J, Koehler K, Talley A, Lustberg M. Endocrine Therapy in Breast Cancer: The Neoadjuvant, Adjuvant, and Metastatic Approach. Seminars In Oncology Nursing 2015, 31: 146-155. PMID: 25951743, DOI: 10.1016/j.soncn.2015.02.002.
Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancerOostra D, Lustberg M, Reinbolt R, Pan X, Wesolowski R, Shapiro C. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer. Molecular And Cellular Endocrinology 2015, 402: 51-56. PMID: 25575458, PMCID: PMC4316829, DOI: 10.1016/j.mce.2014.12.028.
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionBerger M, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro C, Lustberg M. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2014, 23: 2019-2024. PMID: 25519756, PMCID: PMC4804339, DOI: 10.1007/s00520-014-2556-x.
Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicinPahouja G, Wesolowski R, Reinbolt R, Tozbikian G, Berger M, Mangini N, Lustberg M. Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin. Cancer Treatment And Research Communications 2014, 3: 28-32. PMID: 25914871, PMCID: PMC4408922, DOI: 10.1016/j.ctrc.2014.11.002.
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growthMathsyaraja H, Thies K, Taffany D, Deighan C, Liu T, Yu L, Fernandez S, Shapiro C, Otero J, Timmers C, Lustberg M, Chalmers J, Leone G, Ostrowski M. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 2014, 34: 3651-3661. PMID: 25241894, PMCID: PMC4369473, DOI: 10.1038/onc.2014.294.
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancerZhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E, Wesolowski R, Carothers S, Puhalla S, Shapiro C, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Investigational New Drugs 2014, 32: 1285-1294. PMID: 24894652, PMCID: PMC4303337, DOI: 10.1007/s10637-014-0122-5.
Management options for established chemotherapy-induced peripheral neuropathyPachman D, Watson J, Lustberg M, Wagner-Johnston N, Chan A, Broadfield L, Cheung Y, Steer C, Storey D, Chandwani K, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi C. Management options for established chemotherapy-induced peripheral neuropathy. Supportive Care In Cancer 2014, 22: 2281-2295. PMID: 24879391, DOI: 10.1007/s00520-014-2289-x.
Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC).Wesolowski R, Zhao M, Geyer S, Lustberg M, Mrozek E, Layman R, Macrae E, Zhang J, Hall N, Schregel K, Ottman S, Camp A, Chalmers J, Andreopoulou E, Villalona-Calero M, Shapiro C, Knopp M, Grever M, Ramaswamy B. Phase I trial of the PARP inhibitor veliparib (V) in combination with carboplatin (C) in metastatic breast cancer (MBC). Journal Of Clinical Oncology 2014, 32: 1074-1074. DOI: 10.1200/jco.2014.32.15_suppl.1074.
Clinical and genetic risk factors for AI-induced arthralgia.Miller K, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Clinical and genetic risk factors for AI-induced arthralgia. Journal Of Clinical Oncology 2014, 32: e20601-e20601. DOI: 10.1200/jco.2014.32.15_suppl.e20601.
Risk factors for anthracycline-associated cardiotoxicity.Reinbolt R, Patel R, Pan X, Timmers C, Pilarski R, Shapiro C, Lustberg M. Risk factors for anthracycline-associated cardiotoxicity. Journal Of Clinical Oncology 2014, 32: e20583-e20583. DOI: 10.1200/jco.2014.32.15_suppl.e20583.
Treatment‐Related Mortality With Everolimus in Cancer PatientsWesolowski R, Abdel‐Rasoul M, Lustberg M, Paskell M, Shapiro C, Macrae E. Treatment‐Related Mortality With Everolimus in Cancer Patients. The Oncologist 2014, 19: 661-668. PMID: 24794158, PMCID: PMC4041666, DOI: 10.1634/theoncologist.2013-0355.
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineHershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patientsLustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.
Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodologyWu Y, Deighan C, Miller B, Balasubramanian P, Lustberg M, Zborowski M, Chalmers J. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 2013, 64: 169-182. PMID: 24056212, PMCID: PMC3874448, DOI: 10.1016/j.ymeth.2013.09.006.
Association of osteprotegerin, bone turnover, and bone loss after adjuvant chemotherapy in early-stage breast cancer.Oostra D, Lustberg M, Pan X, Shapiro C. Association of osteprotegerin, bone turnover, and bone loss after adjuvant chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2013, 31: 134-134. DOI: 10.1200/jco.2013.31.26_suppl.134.
Integrative model for breast cancer survivorship.Reinbolt R, Shapiro C, Garrett J, Basinger H, Lester J, Muscari N, Ries K, Lustberg M. Integrative model for breast cancer survivorship. Journal Of Clinical Oncology 2013, 31: 132-132. DOI: 10.1200/jco.2013.31.26_suppl.132.
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapyWenzell C, Berger M, Blazer M, Crawford B, Griffith N, Wesolowski R, Lustberg M, Phillips G, Ramaswamy B, Mrozek E, Flynn J, Shapiro C, Layman R. Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Supportive Care In Cancer 2013, 21: 2845-2851. PMID: 23748485, PMCID: PMC3769492, DOI: 10.1007/s00520-013-1865-9.
Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumorsAggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg M, Ray A, Pompili V, Shapiro C, Das H. Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival‐, apoptosis‐related molecules and microenvironment in tumors. International Journal Of Cancer 2013, 133: 2133-2144. PMID: 23595559, PMCID: PMC3939063, DOI: 10.1002/ijc.28217.
NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer.Ramaswamy B, Zhang J, Hall N, Schregel K, Lustberg M, Wesolowski R, Mrozek E, Layman R, Olson E, Ottman S, Camp A, Chalmers J, Geyer S, Villalona-Calero M, Shapiro C, Grever M, Knopp M. NCI 8609: Interim fluoro-3’-deoxythymidine (FLT) PET imaging findings from the phase I trial of PARP inhibitor veliparib (V) and carboplatin (C) in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 1023-1023. DOI: 10.1200/jco.2013.31.15_suppl.1023.
A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC).Mrozek E, Wesolowski R, Lustberg M, Layman R, Ling Y, Schaaf L, Phelps M, Ivy S, Grever M, Shapiro C. A phase I study of neoadjuvant chemotherapy (NCT) with the gamma secretase (GS) inhibitor RO4929097 in combination with paclitaxel (P) and carboplatin (C) in women with triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2013, 31: 1043-1043. DOI: 10.1200/jco.2013.31.15_suppl.1043.
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.Mateo J, De Bono J, Ramanathan R, Lustberg M, Zivi A, Basset D, Ng M, Young A, Garrett M, Decordova S, Raynaud F, Yap T, Zukiwski A, Proniuk S, Shapiro C. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2608-2608. DOI: 10.1200/jco.2013.31.15_suppl.2608.
Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature reviewPoi M, Berger M, Lustberg M, Layman R, Shapiro C, Ramaswamy B, Mrozek E, Olson E, Wesolowski R. Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Supportive Care In Cancer 2013, 21: 2679-2686. PMID: 23686402, PMCID: PMC3769512, DOI: 10.1007/s00520-013-1842-3.
20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast CancerRamaswamy B, Geyer S, Lustberg M, Wesolowski R, Andreopoulou E, Knopp M, Villalona M, Chen A, Grever M, Shapiro C. 20P NCI 8609: Multicenter Phase I Trial of PARP Inhibitor Veliparib with Carboplatin in Advanced Breast Cancer. Annals Of Oncology 2013, 24: iii19. DOI: 10.1093/annonc/mdt081.1.
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancerLayman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut E, Shapiro C. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemotherapy And Pharmacology 2013, 71: 1183-1190. PMID: 23430121, PMCID: PMC3710373, DOI: 10.1007/s00280-013-2112-2.
Abstract P2-11-04: Chemotherapy Induces Neuroinflammation and Cognitive Deficits in Female MiceJarrett B, Lustberg M, Hinzey A, Stuller K, Shapiro C, DeVries C. Abstract P2-11-04: Chemotherapy Induces Neuroinflammation and Cognitive Deficits in Female Mice. Cancer Research 2012, 72: p2-11-04-p2-11-04. DOI: 10.1158/0008-5472.sabcs12-p2-11-04.
Abstract P2-11-07: Endothelial progenitor cells as novel markers of anthracycline induced cardiac injuryLustberg M, Ruppert A, Carothers S, Bingman A, McCarthy B, Raman S, Das M, Kanji S, Lu J, Das H, Cinar-Akakin H, Gurcan M, Berger M, Wesolowski R, Olson E, Ramaswamy B, Mrozek E, Layman R, Binkley P, Shapiro C. Abstract P2-11-07: Endothelial progenitor cells as novel markers of anthracycline induced cardiac injury. Cancer Research 2012, 72: p2-11-07-p2-11-07. DOI: 10.1158/0008-5472.sabcs12-p2-11-07.
A MagDot-Nanoconveyor Assay Detects and Isolates Molecular Biomarkers.Mahajan K, Vieira G, Ruan G, Miller B, Lustberg M, Chalmers J, Sooryakumar R, Winter J. A MagDot-Nanoconveyor Assay Detects and Isolates Molecular Biomarkers. CEP Magazine 2012, 108: 41-46. PMID: 25580052, PMCID: PMC4286893.
Management of neutropenia in cancer patients.Lustberg M. Management of neutropenia in cancer patients. Clinical Advances In Hematology And Oncology 2012, 10: 825-6. PMID: 23271355, PMCID: PMC4059501.
Bone Health in Adult Cancer SurvivorshipLustberg M, Reinbolt R, Shapiro C. Bone Health in Adult Cancer Survivorship. Journal Of Clinical Oncology 2012, 30: 3665-3674. PMID: 23008309, DOI: 10.1200/jco.2012.42.2097.
Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC).Lustberg M, Miller B, Wu Y, Xue W, Deighan C, Carothers S, Berger M, Shapiro C, Chalmers J. Circulating CD68 positive (+) leukocytes in blood samples from patients (pts) with breast cancer (BC). Journal Of Clinical Oncology 2012, 30: 172-172. DOI: 10.1200/jco.2012.30.27_suppl.172.
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancerYang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.
Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and NeckBalasubramanian P, Lang J, Jatana K, Miller B, Ozer E, Old M, Schuller D, Agrawal A, Teknos T, Summers T, Lustberg M, Zborowski M, Chalmers J. Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck. PLOS ONE 2012, 7: e42048. PMID: 22844540, PMCID: PMC3406036, DOI: 10.1371/journal.pone.0042048.
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanesLustberg M, Pant S, Ruppert A, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen R, Berger M, Mrozek E, Ramaswamy B, Grever M, Au J, Wientjes M, Shapiro C. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemotherapy And Pharmacology 2012, 70: 49-56. PMID: 22729159, PMCID: PMC3466596, DOI: 10.1007/s00280-012-1887-x.
Development of automated quantitative multiparameter immunocytochemical profiling of circulating tumor cells (CTCs) in breast cancer (BC).Miller B, Deighan C, Chalmers J, Lustberg M. Development of automated quantitative multiparameter immunocytochemical profiling of circulating tumor cells (CTCs) in breast cancer (BC). Journal Of Clinical Oncology 2012, 30: e21124-e21124. DOI: 10.1200/jco.2012.30.15_suppl.e21124.
Emerging Technologies for CTC Detection Based on Depletion of Normal CellsLustberg M, Jatana K, Zborowski M, Chalmers J. Emerging Technologies for CTC Detection Based on Depletion of Normal Cells. 2012, 195: 97-110. PMID: 22527498, PMCID: PMC3775349, DOI: 10.1007/978-3-642-28160-0_9.
Abstract 2371: Circulating cancer associated cells co-express epithelial and hematopoietic markers in metastatic breast cancer (MBC) patients (pts)Lustberg M, Balasubramanian P, Miller B, Villa A, Xue W, Wu Y, Chalmers J, Shapiro C. Abstract 2371: Circulating cancer associated cells co-express epithelial and hematopoietic markers in metastatic breast cancer (MBC) patients (pts). Cancer Research 2012, 72: 2371-2371. DOI: 10.1158/1538-7445.am2012-2371.
Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609)Ramaswamy B, Lustberg M, Wesolowski R, Layman R, Mrozek E, Olson E, Andreopoulou E, Garcia-Villa A, Chalmers J, Cotrill J, Nutter J, Ledin J, Schaaf L, Bajestani S, Zhao W, Geyer S, Chen A, Shapiro C, Villalona-Calero M, Knopp M, Grever M. Abstract 5586: Phase I study of PARP inhibitor ABT-888 and carboplatin with novel imaging in metastatic breast cancer (MBC) (NCI-8609). Cancer Research 2012, 72: 5586-5586. DOI: 10.1158/1538-7445.am2012-5586.
Abstract 531: Human γδ T cells limit breast tumor growth partly by down regulating cell survival-related molecules and up regulating apoptosis-related molecules in tumor cellsAggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg M, Pompili V, Shapiro C, Das H. Abstract 531: Human γδ T cells limit breast tumor growth partly by down regulating cell survival-related molecules and up regulating apoptosis-related molecules in tumor cells. Cancer Research 2012, 72: 531-531. DOI: 10.1158/1538-7445.am2012-531.
Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapyGarcia-Villa A, Balasubramanian P, Miller B, Lustberg M, Ramaswamy B, Chalmers J. Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Frontiers In Oncology 2012, 2: 128. PMID: 23112954, PMCID: PMC3480704, DOI: 10.3389/fonc.2012.00128.
PD10-01: Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer.Ramaswamy B, Srividya V, Mullins D, Carothers S, Young G, Wenrui D, Zhao W, Lustberg M, Leon M, Weslowski R, Layman R, Mrozek E, Shapiro C, Villalona-Calero M. PD10-01: Prevalence of Dysfunctional Fanconi Anemia (FA) DNA Repair Pathway in Breast Cancer. Cancer Research 2011, 71: pd10-01-pd10-01. DOI: 10.1158/0008-5472.sabcs11-pd10-01.
Pneumocystis jiroveci Pneumonia in an Atypical HostReinbolt R, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci Pneumonia in an Atypical Host. Clinical Breast Cancer 2011, 12: 138-141. PMID: 22133356, PMCID: PMC3498486, DOI: 10.1016/j.clbc.2011.10.003.
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reactionBerger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.
EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC).Lustberg M, Balasubramanian P, Miller B, Garcia Villa A, Carothers S, Michael B, Mrozek E, Ramaswamy B, Layman R, Wesolowski R, Shapiro C, Chalmers J. EpCAM-negative cancer–associated circulating cells (CACS) in blood samples of women with triple-negative breast cancer (TNBC). Journal Of Clinical Oncology 2011, 29: e11559-e11559. DOI: 10.1200/jco.2011.29.15_suppl.e11559.
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast CancerLustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.
Epigenetic Therapy in Breast CancerLustberg M, Ramaswamy B. Epigenetic Therapy in Breast Cancer. Current Breast Cancer Reports 2010, 3: 34-43. PMID: 23097683, PMCID: PMC3477864, DOI: 10.1007/s12609-010-0034-0.
Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast CancerLayman R, Ruppert A, Lynn M, Mrozek E, Ramaswamy B, Lustberg M, Susan O, Carothers S, Kraut E, Shapiro C. Severe and Prolonged Lymphopenia Observed In Patients Treated with Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer. Blood 2010, 116: 1739-1739. DOI: 10.1182/blood.v116.21.1739.1739.
Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI).Mrozek E, Lustberg M, Knopp M, Spigos D, Yang X, Houton L, Ramaswamy B, Layman R, Povoski S, Agnese D. Phase II trial of neoadjuvant chemotherapy (NCT) with weekly nanoparticle albumin-bound paclitaxel (Nab-P), carboplatin (CBP), and bevacizumab (BEV) in women with clinical stages II-III breast cancer (BC): Pathologic response prediction by changes in angiogenic volume (AV) by dynamic contrast magnetic resonance imaging (DCE-MRI). Journal Of Clinical Oncology 2010, 28: 604-604. DOI: 10.1200/jco.2010.28.15_suppl.604.
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal AdenocarcinomaLustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.
Abstract 3284: Isolation of circulating tumor cells (CTCs) with mesenchymal and stem cell markers in localized and metastatic breast cancer using a novel negative selection enrichmentLustberg M, Balasubramanian P, Lang J, Ruppert A, Carothers S, Berger M, Mrozek E, Ramaswamy B, Layman R, Chalmers J, Shapiro C. Abstract 3284: Isolation of circulating tumor cells (CTCs) with mesenchymal and stem cell markers in localized and metastatic breast cancer using a novel negative selection enrichment. Cancer Research 2010, 70: 3284-3284. DOI: 10.1158/1538-7445.am10-3284.
Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I studyLustberg M, Nuovo J, Thomas J, Monk P, Kim S, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. Journal Of Clinical Oncology 2009, 27: 2569-2569. DOI: 10.1200/jco.2009.27.15_suppl.2569.
Epigenetic targeting in breast cancer: therapeutic impact and future direction.Lustberg M, Ramaswamy B. Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News & Perspectives 2009, 22: 369-81. PMID: 19890494, PMCID: PMC3658161, DOI: 10.1358/dnp.2009.22.7.1405072.
Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts)Lustberg M, Bekaii-Saab T, Diasio R, Ezzeldin H, Starrett S, Otterson G, Villalona M. Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts). Journal Of Clinical Oncology 2008, 26: 19090-19090. DOI: 10.1200/jco.2008.26.15_suppl.19090.
FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphomaLustberg M, Aras O, Meisenberg B. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. European Journal Of Haematology 2008, 81: 154-156. PMID: 18462255, DOI: 10.1111/j.1600-0609.2008.01088.x.
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung CancerLustberg M, Edelman M. Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options In Oncology 2007, 8: 38-46. PMID: 17634834, DOI: 10.1007/s11864-007-0020-6.

Clinical Trials

Conditions	Study Title
Breast	An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)
Breast	The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Breast	A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Breast	Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Breast - Female	I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)
Breast	A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)
Breast	A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)
Breast	A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Edit Profile

Maryam Lustberg, MD, MPH

Contact Information

Related Links

Patient Care

Research & Publications

Biography